<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">33480</article-id><article-id pub-id-type="doi">10.7554/eLife.33480</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-101019"><name><surname>Knowles</surname><given-names>David A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7408-146X</contrib-id><email>knowles84@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-101020"><name><surname>Burrows</surname><given-names>Courtney K</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/><xref ref-type="other" rid="dataset2"/></contrib><contrib contrib-type="author" id="author-101021"><name><surname>Blischak</surname><given-names>John D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2634-9879</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/><xref ref-type="other" rid="dataset2"/></contrib><contrib contrib-type="author" id="author-101078"><name><surname>Patterson</surname><given-names>Kristen M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset2"/></contrib><contrib contrib-type="author" id="author-111067"><name><surname>Serie</surname><given-names>Daniel J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-111068"><name><surname>Norton</surname><given-names>Nadine</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101023"><name><surname>Ober</surname><given-names>Carole</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/><xref ref-type="other" rid="dataset2"/></contrib><contrib contrib-type="author" id="author-7859"><name><surname>Pritchard</surname><given-names>Jonathan K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8828-5236</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/><xref ref-type="other" rid="dataset2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-2844"><name><surname>Gilad</surname><given-names>Yoav</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8284-8926</contrib-id><email>gilad@uchicago.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/><xref ref-type="other" rid="dataset2"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Genetics</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Radiology</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Human Genetics</institution><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Health Sciences Research</institution><institution>Mayo Clinic</institution><addr-line><named-content content-type="city">Jacksonville</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Cancer Biology</institution><institution>Mayo Clinic</institution><addr-line><named-content content-type="city">Jacksonville</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Biology</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Howard Hughes Medical Institute</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Department of Medicine</institution><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1141"><name><surname>McVean</surname><given-names>Gilean</given-names></name><role>Reviewing Editor</role><aff id="aff9"><institution>Oxford University</institution><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>05</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e33480</elocation-id><history><date date-type="received" iso-8601-date="2017-11-11"><day>11</day><month>11</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2018-04-30"><day>30</day><month>04</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Knowles et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Knowles et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-33480-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.33480.001</object-id><p>Anthracycline-induced cardiotoxicity (ACT) is a key limiting factor in setting optimal chemotherapy regimes, with almost half of patients expected to develop congestive heart failure given high doses. However, the genetic basis of sensitivity to anthracyclines remains unclear. We created a panel of iPSC-derived cardiomyocytes from 45 individuals and performed RNA-seq after 24 hr exposure to varying doxorubicin dosages. The transcriptomic response is substantial: the majority of genes are differentially expressed and over 6000 genes show evidence of differential splicing, the later driven by reduced splicing fidelity in the presence of doxorubicin. We show that inter-individual variation in transcriptional response is predictive of in vitro cell damage, which in turn is associated with in vivo ACT risk. We detect 447 response-expression quantitative trait loci (QTLs) and 42 response-splicing QTLs, which are enriched in lower ACT GWAS <inline-formula><mml:math id="inf1"><mml:mi>p</mml:mi></mml:math></inline-formula>-values, supporting the in vivo relevance of our map of genetic regulation of cellular response to anthracyclines.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.33480.002</object-id><title>eLife digest</title><p>Many cancers, including leukaemia, lymphoma and breast cancer, are treated with potent chemotherapy drugs such as anthracyclines. However, anthracyclines have strong side effects known as anthracycline cardiotoxicity, which affect the health of the heart. Almost half of the patients given high doses of anthracyclines develop chronic heart failure.</p><p>While anthracycline cardiotoxicity is very common, people’s genes may contribute to how sensitive they are to these drugs but it is not understood which genes can cause this effect. Previous studies using only a small number of participants have not been able to pin down the genetic factors that make some patients respond well to anthracyclines, and others prone to developing heart failure when taking these drugs.</p><p>To find out which genes affect anthracycline cardiotoxicity, Knowles, Burrows et al. transformed blood cells from 45 individuals into stem cells, which were then developed into heart muscle cells. Then, the activity of genes was analyzed by measuring the amount of RNA (the template molecules used to make proteins) produced by those genes.</p><p>After the cells had been exposed for 24 hours to the anthracycline drug doxorubicin, hundreds of gene activity differences could be found in the heart muscle cells between individuals. Some of these differences were linked to poorer health of the cells after treatment with the drug. As a result, a number of genetic variants that could predispose patients to the side effects of doxorubicin were discovered. The experiments also revealed how doxorubicin disrupts an important process that separates ‘junk’ parts of the RNA from the parts that are used as a template for proteins.</p><p>Being able to predict who is likely to be sensitive to drugs such as doxorubicin could help doctors to tailor chemotherapy treatments more effectively, minimising the risk of heart failure. In future, larger studies could lead to accurate predictions of a patient’s response to a particular chemotherapy drug to personalize their cancer treatment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>anthracycline-induced toxicity</kwd><kwd>response expression QTL</kwd><kwd>iPSC-derived differentiated cells</kwd><kwd>Doxorubicin</kwd><kwd>oxidative damage</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>HL092206</award-id><principal-award-recipient><name><surname>Gilad</surname><given-names>Yoav</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pritchard</surname><given-names>Jonathan K</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>HG008140</award-id><principal-award-recipient><name><surname>Pritchard</surname><given-names>Jonathan K</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>HG009431</award-id><principal-award-recipient><name><surname>Pritchard</surname><given-names>Jonathan K</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>TL1 TR 432-7</award-id><principal-award-recipient><name><surname>Burrows</surname><given-names>Courtney K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic variants that modulate transcriptomic response to doxorubicin in human iPSC-derived cardiomyocytes are predictive of cardiac damage and in vivo sensitivity to anthracycline cardiotoxicity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Anthracyclines, including the prototypical doxorubicin, continue to be used as chemotherapeutic agents treating a wide range of cancers, particularly leukemia, lymphoma, multiple myeloma, breast cancer, and sarcoma. A well-known side-effect of doxorubicin treatment is anthracycline-induced cardiotoxicity (ACT). For some patients ACT manifests as an asymptomatic reduction in cardiac function, as measured by left ventricular ejection fraction (LVEF), but in more extreme cases ACT can lead to congestive heart failure (CHF). The risk of CHF is dosage-dependent: an early study (<xref ref-type="bibr" rid="bib60">Von Hoff et al., 1979</xref>) estimated 3% of patients at 400 mg/m2, 7% of patients at 550 mg/m2, and 18% of patients at 700 mg/m2 develop CHF, where a more recent study puts these numbers at 5%, 26% and 48% respectively (<xref ref-type="bibr" rid="bib51">Swain et al., 2003</xref>). Reduced LVEF shows a similar dosage-dependent pattern, but is not fully predictive of CHF.</p><p>Perhaps most daunting for patients is that CHF can occur years after treatment: out of 1807 cancer survivors followed for 7 years in a recent survey a third died of heart diseases compared to 51% of cancer recurrence (<xref ref-type="bibr" rid="bib57">Vejpongsa and Yeh, 2014</xref>).</p><p>Various candidate gene studies have attempted to find genetic determinants of ACT, but are plagued by small sample sizes and unclear endpoint definitions, resulting in limited replication between studies. Two ACT genome-wide association studies (GWAS) have been published (<xref ref-type="bibr" rid="bib2">Aminkeng et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Schneider et al., 2017</xref>). While neither found genome-wide significant associations using their discovery cohorts, both found one variant that they were able to replicate in independent cohorts.</p><p>A nonsynonymous coding variant, rs2229774, in <italic>RARG</italic> (retinoic acid receptor <inline-formula><mml:math id="inf2"><mml:mi>γ</mml:mi></mml:math></inline-formula>) was found to be associated with pediatric ACT using a Canadian European discovery cohort of 280 patients (<xref ref-type="bibr" rid="bib2">Aminkeng et al., 2015</xref>), and replicated in both a European (<inline-formula><mml:math id="inf3"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.004</mml:mn></mml:mrow></mml:math></inline-formula>) and non-European cohort (<inline-formula><mml:math id="inf4"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>). Modest signal (<inline-formula><mml:math id="inf5"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.076</mml:mn></mml:mrow></mml:math></inline-formula>) supporting rs2229774’s association with ACT was also reported in a recent study primarily focused on trastuzumab-related cardiotoxicity (<xref ref-type="bibr" rid="bib49">Serie et al., 2017</xref>). <italic>RARG</italic> negative cell lines have reduced retinoic acid response element (RAREs) activity and reduced suppression of <italic>Top2b</italic> (<xref ref-type="bibr" rid="bib2">Aminkeng et al., 2015</xref>), which has been proposed as a mediator of ACT.</p><p>In a different study, a GWAS in 845 patients with European-ancestry from a large adjuvant breast cancer clinical trial, 51 of whom developed CHF, found no variants at genome-wide significance levels (<xref ref-type="bibr" rid="bib47">Schneider et al., 2017</xref>). However, one of the most promising variants, rs28714259 (<inline-formula><mml:math id="inf6"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>9</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> in discovery cohort), was genotyped in two further cohorts and showed modest replication (<inline-formula><mml:math id="inf7"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.04</mml:mn><mml:mo>,</mml:mo><mml:mn>0.018</mml:mn></mml:mrow></mml:math></inline-formula>). rs28714259 falls in a glucocorticoid receptor protein binding peak, which may play a role in cardiac development.</p><p>An exciting approach to studying complex phenotypes, including disease, in human is to use induced pluripotent stem cells (iPSC) and derived differentiated cells as in vitro model systems. Work by us and others has demonstrated that iPSCs and iPSC-derived cell-types are powerful model systems for understanding cell-type specific genetic regulation of transcription (<xref ref-type="bibr" rid="bib52">Thomas et al., 2015</xref>; <xref ref-type="bibr" rid="bib7">Burrows et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Banovich et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Kilpinen et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Alasoo et al., 2017</xref>), but it is less established whether these systems can be used to model the interplay of genetic and environmental factors in disease progression. Encouragingly, the response of iPSC-derived cardiomyocytes (ICs) to doxorubicin was recently extensively characterized (<xref ref-type="bibr" rid="bib5">Burridge et al., 2016</xref>). ICs derived from four individuals who developed ACT after doxorubicin treatment (‘DOXTOX’ group) and four who did not (‘DOX’ group), showed clear differences in viability (via apoptosis), metabolism, DNA damage, oxidative stress and mitochondrial function when exposed to doxorubicin. These observations suggest that ICs recapitulate in vivo inter-individual differences in doxorubicin sensitivity. Gene expression response differences between the DOX and DOXTOX groups were found using RNA-sequencing data, but the sample size was insufficient (RNA-seq was generated for only three individuals in each group) to attempt mapping of genetic variants that might explain the observed functional differences between individuals.</p><p>Here we used a panel of iPSC-derived cardiomyocytes from 45 individuals, exposed to five different drug concentrations, to map the genetic basis of inter-individual differences in doxorubicin-sensitivity. We find hundreds of genetics variants that modulate the transcriptomic response, including 42 that act on alternative splicing. We show that the IC transcriptomic response predicts cardiac troponin levels in culture (indicative of cell lysis) in these cell-lines, and that troponin level is itself predictive of ACT. Finally we demonstrate that the mapped genetic variants show significant enrichment in lower ACT GWAS <inline-formula><mml:math id="inf8"><mml:mi>p</mml:mi></mml:math></inline-formula>-values.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Measuring transcriptomic response to doxorubicin exposure</title><p>We generated iPSC-derived cardiomyocytes (ICs) for 45 Hutterite individuals (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). iPSC quality was confirmed using qPCR (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), global gene expression profiling (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), the embryoid body test (Supplementary Data), and EBV integration analysis (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Cardiomyocyte identity was confirmed by FACS for cardiac troponin I and T, with mean purity (72 ±12)% (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). We exposed all 45 IC lines to doxorubicin at five different concentrations for 24 hr, after which samples were processed for RNA-sequencing. We obtained sufficient read depth (10M exonic reads) for downstream analysis for 217 of the <inline-formula><mml:math id="inf9"><mml:mrow><mml:mn>5</mml:mn><mml:mo>×</mml:mo><mml:mn>45</mml:mn><mml:mo>=</mml:mo><mml:mn>225</mml:mn></mml:mrow></mml:math></inline-formula> individual-concentration pairs, and confirmed sample identity by calling exonic SNPs (see Methods). We observed a strong gene regulatory response to doxorubicin across all concentrations, with 98% (12038/12317) of quantifiable genes (5% FDR) showing differential expression across the different treatment concentrations. Our data shows excellent concordance with the smaller RNA-seq dataset of (<xref ref-type="bibr" rid="bib5">Burridge et al., 2016</xref>) (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>). Principal component analysis (PCA, <xref ref-type="fig" rid="fig1">Figure 1b</xref>) confirms that the main variation in the data is driven by doxorubicin concentration and that the effect of concentration on gene expression is nonlinear. For some individuals the expression data following doxorubicin treatment with <inline-formula><mml:math id="inf10"><mml:mrow><mml:mn>1.25</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> is closer to the data from treatment with <inline-formula><mml:math id="inf11"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>, whereas for others it is closer to data from treatment with <inline-formula><mml:math id="inf12"><mml:mrow><mml:mn>2.5</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>. This general pattern provides the first indication in our data that that there is systematic variation in how different individuals respond to doxorubicin exposure. Since the majority of genes appear responsive to doxorubicin we clustered genes into six distinct response patterns using a mixture model approach (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, see Materials and methods). From largest to smallest, these clusters represent genes that, through the gradient from low to high concentration treatments, are (1) down regulated (2) initially up-regulated, then further down-regulated (3) up-regulated (4) down-regulated only at lower dosages (5) up-regulated only at lower dosages (6) down-regulated then partially recover (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Gene set enrichments (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) for the up-regulated cluster include metabolic, mitochrondrial and extracellular processes, as well as known doxorubicin response genes in breast cancer cell lines from (<xref ref-type="bibr" rid="bib20">Graessmann et al., 2007</xref>) (647 overlapping genes of 1090 in term, hypergeometric <inline-formula><mml:math id="inf13"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>26</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>). The down-regulated cluster shares genes with those down-regulated in response to UV light, which, like doxorubicin, causes DNA-damage (413 overlapping genes of 470 in term, hypergeometric <inline-formula><mml:math id="inf14"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>48</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>). Targets of p53, a transcription factor that responds to DNA damage, are overrepresented in clusters 2 and 5; these clusters involve up-regulation at low concentrations (<inline-formula><mml:math id="inf15"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>) but down-regulation at higher concentrations (486 overlapping genes out of 1057 in term, hypergeometric <inline-formula><mml:math id="inf16"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>39</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>). Promoter analysis (<xref ref-type="fig" rid="fig1s8">Figure 1—figure supplement 8</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) revealed 21, 45, and 6 significantly enriched transcription factor (TF) binding motifs for clusters 1, 2 and 3 respectively (and none for cluster 4–6). Examples include binding sites for <italic>ZNF143</italic>, a TF that promotes <italic>GPX1</italic> activity and protects cells from oxidative damage during mitochondrial respiratory dysfunction (<xref ref-type="bibr" rid="bib36">Lu et al., 2012</xref>), which is enriched in cluster 1 (down regulation w/dox, 318 overlapping genes out of 3555 <italic>ZNF143</italic> targets, hypergeometric <inline-formula><mml:math id="inf17"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>); <italic>RONIN</italic>, a regulator of mitochrondrial development and function (<xref ref-type="bibr" rid="bib44">Poché et al., 2016</xref>), which is enriched in clusters 1 and 2 (217 and 210 overlapping genes out of 2295 targets, <inline-formula><mml:math id="inf18"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf19"><mml:mrow><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> respectively); and <italic>MEF2</italic>, myocyte enhancer factor 2, involved in regulating muscle development, stress-response and p38-mediated apoptosis (<xref ref-type="bibr" rid="bib63">Zarubin and Han, 2005</xref>), enriched in cluster 4 (32 overlapping genes out of 741 targets, hypergeometric <inline-formula><mml:math id="inf20"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.33480.003</object-id><label>Figure 1.</label><caption><title>The transcriptomic response of cardiomyocytes to doxorubicin is substantial.</title><p>(<bold>a</bold>) Cardiomyocytes were derived from lymphoblastoid cell lines (LCLs) of 45 Hutterite individuals, followed by exposure to differing concentrations of doxorubicin and RNA-sequencing. (<bold>b</bold>) PCA of gene expression levels across samples reveals that doxorubicin concentration explains more variance than inter-individual differences, and that the response is non-linear with respect to concentration. Lines connect samples from the same individual. (<bold>c</bold>) A probabilistic mixture model uncovers six distinct patterns of response across genes.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>qPCR for key pluripotency genes for a subset of iPSCs.</title><p>qPCR quality control of iPSC lines. Quantitative PCR (qPCR) of pluripotency genes <italic>OCT3/4</italic>, <italic>NANOG</italic>, and <italic>SOX2</italic> on randomly selected Hutterite iPSC lines (denoted by *). Relative expression is the RQ value with respect to <italic>GAPDH</italic> expression, with error bars representing the calculated min and max RQ value. All iPSC lines show endogenous expression of these pluripotency genes. Two original LCL lines are included as control and show little or no expression of pluripotency genes.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Genome-wide expression analysis of iPSCs using PluriTest.</title><p>PluriTest quality control of iPSCs. PluriTest pluriscore and novelty results shows all iPSC samples fall within the pluripotent and novelty threshold (black lines). All cell lines received a pluripotency score above the pluripotency classification threshold of 20 (average = 27.38) and showed low novelty scores below the threshold of 1.67 (average = 1.34). As a comparison, a subset of the iPSC-cardiomyocytes fall outside of the pluripotency classification for both pluriscore and novelty.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp2-v2"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.006</object-id><label>Figure 1—figure supplement 3.</label><caption><title>EBV integration analysis of iPSCs.</title><p>EBV presence/absence quality control of iPSCs.</p><p>(<bold>a</bold>) PCR on DNA for presence or absence of EBV, both integrated and non-integrated (reprogramming vector based). Two iPSC lines had obvious presence of EBV (16, 54) and one was unclear (14). Additional banding in the images was due to RNA in the sample. The three samples, highlighted by a red box, were taken forward for two additional PCRs. First, the three samples were tested for EBV based on the presence of the LMP-2A sequence (<bold>b</bold>); an EBV gene not found on the reprogramming vector), of which lines 16 and 54 were positive. Lastly, the three samples were tested for the presence of the reprogramming vectors (<bold>c</bold>), of which no samples were positive. Controls were ordered as followed for all PCRs: mixture of chimp and human fibroblast DNA at 10 ng/<inline-formula><mml:math id="inf21"><mml:mi>μ</mml:mi></mml:math></inline-formula>L with all reprogramming plasmids at 0.02 pg/<inline-formula><mml:math id="inf22"><mml:mi>μ</mml:mi></mml:math></inline-formula>L), mixture of two LCL lines DNA at 10 ng/<inline-formula><mml:math id="inf23"><mml:mi>μ</mml:mi></mml:math></inline-formula>L, mixture of human and chimp fibroblast DNA at 10 ng/<inline-formula><mml:math id="inf24"><mml:mi>μ</mml:mi></mml:math></inline-formula>L without any plasmid, and no sample blank.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp3-v2"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.007</object-id><label>Figure 1—figure supplement 4.</label><caption><title>qPCR of <italic>EBNA-1 to assess EBV status in iPSCs.</italic></title><p>Quantitative PCR of EBNA-1 quality control of iPSC Lines. Quantitative PCR (qPCR) of EBV-required gene EBNA-1. Lines 16 and 54 which both showed the presence of genomic integrations of EBV (as shown in Fig. <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>) are the only iPSC lines that have EBNA-1 expression. Line 14 is again confirmed as not having EBV.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp4-v2"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.008</object-id><label>Figure 1—figure supplement 5.</label><caption><title>Fluorescence activated cell sorting (FACS) purity estimates for iPSC-derived cardiomyocytes.</title></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp5-v2"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.009</object-id><label>Figure 1—figure supplement 6.</label><caption><title>Our expression data is concordant with an existing small RNA-seqdataset (<xref ref-type="bibr" rid="bib5">Burridge et al., 2016</xref>).</title><p>DOXTOX and DOX correspond to samples from patients that did and did not develop ACT after doxorubicin chemotherapy respectively. We additionally see that the transcriptional response at higher concentrations cannot be extrapolated from that at lower concentrations. Higher concentrations are not shown since including these compresses the first PC obscuring the relevant variation.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp6-v2"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.010</object-id><label>Figure 1—figure supplement 7.</label><caption><title>Gene set enrichment analysis of genes in each response cluster confirms expected patterns: metabolic, mitochrondrial and DNA damage processes, as well as existing doxorubicin response genes.</title></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp7-v2"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.011</object-id><label>Figure 1—figure supplement 8.</label><caption><title>Enrichment of transcription factor binding motifs for each response pattern, using HOMER.</title><p>** denotes <italic>q &lt;</italic> 0:05, * denotes <italic>q &lt;</italic> 0:5.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig1-figsupp8-v2"/></fig></fig-group></sec><sec id="s2-2"><title>Mapping variants modulating doxorubicin response</title><p>We next sought to map single nucleotide polymorphisms (SNPs) that modulate the observed inter-individual transcriptomic response to doxorubicin, leveraging available genetic variation across the 45 individuals (<xref ref-type="bibr" rid="bib35">Livne et al., 2015</xref>). We developed a linear mixed model approach, called suez, that extends the PANAMA framework (<xref ref-type="bibr" rid="bib16">Fusi et al., 2012</xref>) to account for relatedness amongst individuals, repeat measurements, multiple conditions and latent confounding. Testing SNPs within 1 Mb of the transcription start site (TSS), 518 genes have a variant with a detectable marginal effect on expression (5% FDR, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Using a mutual information approach (see Methods) which, unlike a naive replication analysis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), controls for differential power across GTEx tissues, we find our expression quantitative trait loci (eQTLs) show stronger overlap with the two heart tissues than any other GTEx tissue (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Remarkably, even with our moderate number of individuals, we are able to detect many response-eQTLs (reQTLs), i.e. variants that modulate (directly or indirectly) transcriptomic response to doxorubicin. We found reQTLs for 376 genes at a nominal 5% FDR (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>), which we estimate using a parametric bootstrap corresponds to a true FDR of <inline-formula><mml:math id="inf25"><mml:mrow><mml:mn>8.5</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). We explored leveraging allele specific expression (ASE) extending our previous work (<xref ref-type="bibr" rid="bib27">Knowles et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">van de Geijn et al., 2015</xref>). We fit a beta-binomial generalized linear model (GLM) where the response variable corresponds to alternative vs reference read counts and the independent variable is the heterozygosity of the test regulatory eSNP. We found it impractical to directly relate effect sizes in the total expression and ASE models so we instead combined likelihood ratios from the beta-binomial GLM and suez likelihood into a single test statistic. This approach yielded 447 reQTLs at 5% FDR (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>), an increase of 19% over using total expression alone. We hypothesize that this relatively modest increase in power is due to a) suez already being reasonably well powered in this direct perturbation setting and b) the somewhat low sequencing depth of our samples.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.33480.012</object-id><label>Figure 2.</label><caption><title>Genetic variation regulates the transcriptomic response to doxorubicin exposure.</title><p>(<bold>a</bold>) Marginal eQTLs show strong replication in GTEx heart data, and lower replication in other tissues (LCL = lymphoblastoid cell line). (<bold>b</bold>) We detect 100 s of response-eQTLs (reQTLs): variants that modulate response to doxorubicin. The false positive rate (FPR) is estimated using a parametric bootstrap. (<bold>c</bold>) We developed a statistical method to assign the major and minor allele response to one of the six clusters from <xref ref-type="fig" rid="fig1">Figure 1c</xref>. The strongest 46% of detected reQTLs result in a discretely different response, whereas the remainder only modulate the response. (<bold>d</bold>) For significant reQTLs we calculated relative genotype effect sizes by dividing the fitted effect size at each concentration by the (signed) effect size with the largest absolute value. <inline-formula><mml:math id="inf26"><mml:mi>K</mml:mi></mml:math></inline-formula>-means clustering of these effect size profiles reveals distinct patterns, the most common being a small reduction in absolute effect size from <inline-formula><mml:math id="inf27"><mml:mn>0</mml:mn></mml:math></inline-formula> to <inline-formula><mml:math id="inf28"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> followed by the largest effects being at the highest concentrations. (<bold>e</bold>) An example response-eQTL where rs112594884 regulates the response of the mitochondrial complex I chaperone NDUFAF1. Under the major (T) allele we see moderate down-regulation at <inline-formula><mml:math id="inf29"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> followed by up-regulation at higher concentrations. Under the minor (G) allele, there is little change at <inline-formula><mml:math id="inf30"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> followed by substantial down-regulation. Since the genotype effects are reduced at <inline-formula><mml:math id="inf31"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> and largest at high concentrations this reQTL is assigned to cluster 1 of panel d.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.013</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Using <inline-formula><mml:math id="inf32"><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> statistics to assess replication is confounded by different sample size/power across GTEx tissues.</title><p>Storey’s <inline-formula><mml:math id="inf33"><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> values to estimate the replication in GTEx tissues of SNP-gene eQTL pairs significant in our data at <inline-formula><mml:math id="inf34"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>.This analysis is confounded by variable power across the GTEx tissues.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.014</object-id><label>Figure 2—figure supplement 2.</label><caption><title>A mutual information approach to control for different sample sizes/power across GTEx tissues.</title><p>Estimates of the mutual information between whether SNP-gene pairs are associated in our data compared to all 48 GTEx tissues. Unlike a simple replication analysis our approach controls for differential power across the GTEx tissues (see Materials and methods) and shows that our eQTLs agree most strongly with eQTLs from the two heart tissues.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig2-figsupp2-v2"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.015</object-id><label>Figure 2—figure supplement 3.</label><caption><title>An example response expression QTL that may act through buffering at high expression levels.</title></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig2-figsupp3-v2"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.016</object-id><label>Figure 2—figure supplement 4.</label><caption><title>Trans-eQTLs for rs2229774 in <italic>RARG</italic>.</title><p>Trans-eQTLs (5 response and one marginal) at 5% FDR for rs2229774, a non-synonymous coding variant in <italic>RARG</italic> which is associated with ACT (<xref ref-type="bibr" rid="bib2">Aminkeng et al., 2015</xref>). Only two individuals are heterozygous. <inline-formula><mml:math id="inf35"><mml:mi>p</mml:mi></mml:math></inline-formula>-values shown have been adjusted for multiple testing by Benjamini Hochberg.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig2-figsupp4-v2"/></fig></fig-group><p>To characterize the detected reQTLs we assigned the response of the major and minor allele to one of the six clusters previously learned (<xref ref-type="fig" rid="fig1">Figure 1c</xref>), with heterozygotes expected to display the average of the two homozygous responses. 172 (46%) of reQTLs result in a qualitatively distinct response as determined by the two alleles being assigned to different clusters. The most common transition, occurring for 33 reQTLs, is that the major allele is associated with simple down-regulation (cluster 1) in response to doxorubicin, whereas the minor allele shows up-regulation at low concentration followed by down-regulation at higher concentration (cluster 2).</p><p>We further broke-down the significant reQTLs by considering the effect of genotype on expression at each concentration (<inline-formula><mml:math id="inf36"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> in <xref ref-type="disp-formula" rid="equ7">Equation 6</xref>). We normalized the effect sizes relative to the <inline-formula><mml:math id="inf37"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> with the largest absolute value, i.e. we consider <inline-formula><mml:math id="inf38"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>g</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mo>|</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:msup><mml:mi>c</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, so that the largest genotype effect always corresponds to a normalized value of 1. The resulting normalized effect profiles were split into nine clusters using <inline-formula><mml:math id="inf39"><mml:mi>k</mml:mi></mml:math></inline-formula>-means clustering (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). The largest cluster (cluster 1, 85 reQTLs) represents reQTLs with a modest effect size at low concentrations (<inline-formula><mml:math id="inf40"><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>) which is amplified at higher concentrations (<xref ref-type="fig" rid="fig2">Figure 2e</xref> shows a highly significant example). Cluster two corresponds to reQTLs whose effect size is attenuated at the <inline-formula><mml:math id="inf41"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> treatment: examples of reQTLs in this cluster tend to be associated with higher expression level at the <inline-formula><mml:math id="inf42"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> treatment (e.g. rs16853200’s association with ABCA12 response, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>).</p><p>A non-synonymous coding variant in <italic>RARG</italic>, rs2229774, was previously associated with ACT (<xref ref-type="bibr" rid="bib2">Aminkeng et al., 2015</xref>). Since <italic>RARG</italic> codes for a transcription factor we searched transcriptome-wide for rs2229774 trans-eQTLs: genes where the expression response to doxorubicin appears to be different for different <italic>RARG</italic> alleles. Only two of the individuals in our panel carry the alternative A allele (as heterozygotes) with the rest being homozygous reference (GG). While this limits statistical power, suez detects one marginal effect (<italic>RECQL</italic>) and five response trans-eQTLs (<italic>NMRK1</italic>, <italic>VMA21</italic>, <italic>PAQR3</italic>, <italic>SGIP1</italic> and <italic>LRRC2</italic>) at 5% FDR (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). Interestingly PAQR3, a membrane protein localized to the Golgi apparatus, is a negative regulator of antioxidant response through the Nrf2-Keap1 pathway (<xref ref-type="bibr" rid="bib65">Zhang et al., 2016</xref>). <italic>LRRC2</italic> is a mitochondrial protein whose RNA expression level has been previous linked with heart failure (<xref ref-type="bibr" rid="bib38">McDermott-Roe et al., 2017</xref>).</p></sec><sec id="s2-3"><title>Doxorubicin exposure reduces splicing fidelity</title><p>Oxidative stress, a major downstream consequence of doxorubicin exposure, disrupts splicing of individual genes including <italic>HPRT</italic>, <italic>POLB</italic> (<xref ref-type="bibr" rid="bib12">Disher and Skandalis, 2007</xref>), and <italic>SMA</italic> (<xref ref-type="bibr" rid="bib48">Seo et al., 2016</xref>). We queried the extent to which doxorubicin exposure disrupts splicing patterns across the transcriptome using LeafCutter (<xref ref-type="bibr" rid="bib31">Li et al., 2017</xref>). Across all samples LeafCutter detected 27769 alternative splicing ‘clusters’ (referred to here as ‘ASCs’ to avoid confusion with <inline-formula><mml:math id="inf43"><mml:mi>k</mml:mi></mml:math></inline-formula>-means clusters), which correspond approximately to splicing events, with a median of 3.0 splice junctions per ASC. Of 17755 ASCs with sufficient coverage to test, 10430 (59%), corresponding to 6398 unique genes, showed an effect of doxorubicin exposure on splicing outcomes (5% FDR, <xref ref-type="supplementary-material" rid="supp7">Supplementary files 7</xref>–<xref ref-type="supplementary-material" rid="supp8">8</xref>). To characterize these changes we calculated the entropy of the splicing choices made for each significant ASC at each concentration and used <inline-formula><mml:math id="inf44"><mml:mi>k</mml:mi></mml:math></inline-formula>-means clusters patterns of change in entropy (<xref ref-type="fig" rid="fig3">Figure 3a</xref> ). The largest cluster has 6166 ASCs (59%), and corresponds to the null of no clear change in entropy across concentrations. Clusters 2 (<inline-formula><mml:math id="inf45"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1136</mml:mn></mml:mrow></mml:math></inline-formula>) and 5 (<inline-formula><mml:math id="inf46"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>475</mml:mn></mml:mrow></mml:math></inline-formula>) correspond to increasing entropy with concentration, and clusters 3, 4, 6, 8 and 9 correspond to the maximum entropy being at different concentrations and reaching different maximum levels. Interestingly, only the relatively small cluster 8 (<inline-formula><mml:math id="inf47"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>304</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></inline-formula> of ACSs) corresponds to a reduction in entropy at higher concentrations, suggesting the dominant behavior is reduced splicing fidelity and increased alternative splicing in response to doxorubicin.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.33480.017</object-id><label>Figure 3.</label><caption><title>Doxorubicin exposure significantly impacts alternative splicing.</title><p>(<bold>a</bold>) The entropy of splicing choices increases in response to doxorubicin exposure. We measured splicing entropy at different concentrations within LeafCutter ‘Alternative Splicing Clusters’ (ACSs) and clustered these into patterns of entropy change. (<bold>b</bold>) We separated introns differentially excised with <inline-formula><mml:math id="inf48"><mml:mrow><mml:mi>Δ</mml:mi><mml:mi>Ψ</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula> into eight clusters based on their relative excision level at each concentration. Introns in clusters corresponding to increased excision at higher doxorubicin concentrations (e.g. cluster 2) are far more likely to use a cryptic (unannotated) splice site at at least one end. <inline-formula><mml:math id="inf49"><mml:mi>p</mml:mi></mml:math></inline-formula>-values shown are for a hypergeometric test of that cluster against all others. (<bold>c</bold>) We mapped 42 ASCs with response splicing QTLs, variants that modulate the differential splicing response to doxorubicin.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-33480-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.018</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Alternative TSS use in NDUFAF6 on doxorubicin exposure.</title><p>Doxorubicin exposure results in the use of a downstream alternative TSS for NDUFAF6 which uncovers an association between rs896853 genotype and inclusion of the exon at chr8:94975318–94975415.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig3-figsupp1-v2"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.019</object-id><label>Figure 3—figure supplement 2.</label><caption><title>The ACT-sensitivity variant rs28714259 weakly modulates TUBGCP5’s response to doxorubicin.</title><p>rs28714259, the one replicated variant from (<xref ref-type="bibr" rid="bib47">Schneider et al., 2017</xref>) is in high LD (<inline-formula><mml:math id="inf50"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.98</mml:mn></mml:mrow></mml:math></inline-formula>) with rs11855704, which is a nominally significant (<inline-formula><mml:math id="inf51"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.036</mml:mn></mml:mrow></mml:math></inline-formula>) eQTL for TUBGCP5. TUBGCP5 is strongly down-regulated in the presence of doxorubicin.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig3-figsupp2-v2"/></fig></fig-group><p>We further tested the hypothesis that splicing fidelity decreases in the presence of doxorubicin by comparing patterns of intronic percent excised (<inline-formula><mml:math id="inf52"><mml:mi>Ψ</mml:mi></mml:math></inline-formula>) with canonical vs cryptic (unannotated) splice site usage. We clustered the 7792 introns in significantly differentially spliced ASC, that have a change in percent excised <inline-formula><mml:math id="inf53"><mml:mrow><mml:mi>Δ</mml:mi><mml:mi>Ψ</mml:mi></mml:mrow></mml:math></inline-formula><inline-formula><mml:math id="inf54"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula> for some pair of concentrations, into eight response patterns based on their relative excision proportions across concentrations. For each cluster we calculated the proportion of member introns with neither end annotated, one end unannotated, or both ends annotated (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). The clusters representing increased <inline-formula><mml:math id="inf55"><mml:mi>Ψ</mml:mi></mml:math></inline-formula> with concentration (clusters 2, 4, 6 and 7) all show enrichment for cryptic splice site usage. The two most populous clusters (1 and 2) correspond to <inline-formula><mml:math id="inf56"><mml:mi>Ψ</mml:mi></mml:math></inline-formula> decreasing and increasingly continuously with doxorubicin concentration, respectively, and the difference in levels of cryptic splicing is extremely apparent (hypergeometric <inline-formula><mml:math id="inf57"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>16</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, odds ratio for one annotated end vs two is <inline-formula><mml:math id="inf58"><mml:mrow><mml:mn>28.0</mml:mn></mml:mrow></mml:math></inline-formula>).</p><p>We additionally used LeafCutter quantification of percentage spliced in (PSI) for each splice junction to map splicing QTLs (sQTL) and response-splicing QTLs (rsQTL) using suez. We tested SNPs within 100 kb of either end of the splice junction. At 5% FDR we found 467 ASCs with a marginal effect sQTL (<xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>) and 42 with a rsQTL (<xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>). An example rsQTL is rs72922482’s association with inclusion of exon 2 of APAF1 Interacting Protein (APIP). Under the major T allele exon skipping is extremely rare: the LeafCutter PSI for the spanning junction ranges from <inline-formula><mml:math id="inf59"><mml:mrow><mml:mn>0.00059</mml:mn></mml:mrow></mml:math></inline-formula> to <inline-formula><mml:math id="inf60"><mml:mrow><mml:mn>0.0049</mml:mn></mml:mrow></mml:math></inline-formula> across concentrations (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). In rs72922482 heterozygotes, however, the exon is skipped in a significant proportion of transcripts, and this effect is most pronounced in the data collected after treatment at <inline-formula><mml:math id="inf61"><mml:mrow><mml:mn>1.25</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>, with approximately 50% exon inclusion, suggesting the minor C allele results in very low inclusion of the cassette exon. Another interesting example is <italic>NDUFAF6</italic>, another mitochrondrial Complex I protein, where doxorubicin exposure (particularly at <inline-formula><mml:math id="inf62"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>) results in increased use of an alternative downstream transcription start site (TSS) which unmasks the influence of rs896853 on a cassette exon between the two alternative TSS (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p></sec><sec id="s2-4"><title>Transcriptional response to doxorubicin is predictive of in-vitro cardiac-damage indicator troponin</title><p>We used the level of cardiac troponin released into the culture media by lysed cardiomyocytes (see Methods, <xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>) to estimate damage occurring as a result of doxorubicin exposure at different concentrations. We observed significant variation in measurable damage caused by doxorubicin across individuals, with 13 of 45 cell lines having a significant correlation between doxorubicin dose and troponin measurement (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). We first sought to determine whether the inter-individual variation in troponin in culture could be explained by variation in the overall gene expression response. Since we are interested in this case in inter-individual differences rather than differences between concentrations we normalized the troponin measurements to have 0 mean and variance of 1 across samples at each doxorubicin treatment. We found 96.1% (95% credible interval <inline-formula><mml:math id="inf63"><mml:mrow><mml:mn>91.5</mml:mn><mml:mi>%</mml:mi><mml:mo>−</mml:mo><mml:mn>98.6</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></inline-formula>) or 91.5% of the variance in this normalized troponin level could be explained using gene expression levels (we excluded the troponin genes <italic>TNNT1-3</italic> and <italic>TNNI1-3</italic> from the analysis) at the corresponding doxorubicin concentrations, using a GREML-analysis (<xref ref-type="bibr" rid="bib61">Yang et al., 2010</xref>) or leave-out-one cross validated (LOOCV) lasso (<xref ref-type="bibr" rid="bib53">Tibshirani, 1996</xref>) respectively. The optimal lasso model included 118 genes (<xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>). To test whether gene expression mediates a link from genotype to troponin level we performed a transcriptome-wide association study (TWAS, <xref ref-type="bibr" rid="bib18">Gamazon et al., 2015</xref>). For each gene we built an elastic-net predictor of expression at each doxorubicin concentration using SNPs within 100 kb, with 10-fold cross-validation to choose the regularization parameters. The fitted predictions (the ‘pre-validation’ values) represent the genetically-determined component of expression. We used the 3840 genes with a statistically significant genetic component (at 1% FDR) to predict troponin level using LOOCV lasso regression. 89% of the variance in normalized troponin level can be explained by the genetic component of 102 genes (<xref ref-type="supplementary-material" rid="supp13">Supplementary file 13</xref>). This analysis is analogous to two-stage least squares Mendelian randomization (<xref ref-type="bibr" rid="bib3">Angrist and Imbens, 1995</xref>) analysis and therefore suggests the existence of a causal link from genotype through gene expression to troponin level, and highlights potential mediating genes. However, further assumptions — in particular that the SNPs and troponin level are independent conditional on gene expression — would be required to formally establish a causal connection.</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.33480.020</object-id><label>Figure 4.</label><caption><title>Transcriptomic response is predictive of doxorubicin induced damage as measured by cardiac troponin.</title><p>(<bold>a</bold>) We measured media levels of cardiac troponin, a sensitive and specific test for myocardial cell damage, in response to doxorubicin, across all cell lines. (<bold>b</bold>) We performed differential expression analyses with respect to troponin at each concentration separately, and observed more differentially expressed genes at higher concentrations corresponding to an increased dynamic range of troponin levels. (<bold>c</bold>) We took differentially expressed genes (5% FDR) at each concentration and checked for ‘replication’ <inline-formula><mml:math id="inf64"><mml:mo>(</mml:mo></mml:math></inline-formula>nominal <inline-formula><mml:math id="inf65"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>) at the other concentrations. Note that no differentially expressed genes were discovered in control condition <inline-formula><mml:math id="inf66"><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>. (<bold>d</bold>) We summarized gene expression response by first fitting a ‘principal curve’ following increasing doxorubicin concentration, and then measuring the rate of progression along this curve for each individual. (<bold>e</bold>) Increased transcriptomic response is associated with reduced cardiac troponin levels, suggesting that the bulk of expression changes we observe are in fact protective against cardiac damage. (<bold>f</bold>) We trained a model to predict ACT risk from gene expression response using available 3 v. 3 case/control data (<xref ref-type="bibr" rid="bib5">Burridge et al., 2016</xref>) and applied this model to our data. Predicted ACT risk correlated significantly with the slope of troponin level (Spearman <inline-formula><mml:math id="inf67"><mml:mrow><mml:mi>ρ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.38</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math></inline-formula>), supporting the in vivo disease relevance of our IC system.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig4-v2"/></fig><p>To further explore the relationship between transcriptomic response and troponin presence in culture, we analyzed differential expression (DE) with respect to troponin measurement at each doxorubicin concentration separately. We found 0, 7, 78, 2984 and 2863 differentially expressed genes (5% FDR, <xref ref-type="supplementary-material" rid="supp14">Supplementary file 14</xref>) at the five concentrations respectively (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). The most strongly DE gene (with respect to effect size) at the <inline-formula><mml:math id="inf68"><mml:mrow><mml:mn>5</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> treatment is <italic>DUSP13</italic>, a known regulator of <italic>ASK1</italic>-mediated apoptosis (<xref ref-type="bibr" rid="bib43">Park et al., 2010</xref>). The large number of DE genes at the <inline-formula><mml:math id="inf69"><mml:mrow><mml:mn>2.5</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf70"><mml:mrow><mml:mn>5.0</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> treatments are broadly shared (nominal replication rate 82 to 85%), and DE genes at the <inline-formula><mml:math id="inf71"><mml:mrow><mml:mn>1.25</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> treatment generally represent the most strongly DE genes at the higher concentrations (<xref ref-type="fig" rid="fig4">Figure 4c</xref>).</p><p>To compare troponin measurements to transcriptomic response we determined an overall per-individual level of transcriptomic response with respect to doxorubicin concentration. To this end we fit a principal curve (<xref ref-type="bibr" rid="bib21">Hastie and Stuetzle, 1989</xref>) through all gene expression samples, initializing the curve to pass sequentially through the successive doxorubicin concentrations (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). Projecting every sample on the principal curve gives a single measure of ‘progression’ through response to doxorubicin at increasing concentrations. We then regressed these values against concentration for each individual to obtain a progression rate. We found the troponin measurement slope is significantly negatively correlated (Spearman <inline-formula><mml:math id="inf72"><mml:mrow><mml:mi>ρ</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>0.42</mml:mn><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.004</mml:mn></mml:mrow></mml:math></inline-formula>, <xref ref-type="fig" rid="fig4">Figure 4e</xref>) with the transcriptomic response rate, suggesting that much of the gene expression program being activated in response to doxorubicin is in fact protective against cardiac damage.</p><p>Using previously published data (<xref ref-type="bibr" rid="bib5">Burridge et al., 2016</xref>), we built a predictive model of ACT risk trained on RNA-seq of ICs exposed to <inline-formula><mml:math id="inf73"><mml:mrow><mml:mn>1</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> doxorubicin from doxorubicin-treated patients who did (‘DOXTOX’, <inline-formula><mml:math id="inf74"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>) or did not (‘DOX’, <inline-formula><mml:math id="inf75"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>) develop ACT. Using lasso with fixed <inline-formula><mml:math id="inf76"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> the optimal model included 17 genes as features (<xref ref-type="supplementary-material" rid="supp15">Supplementary file 15</xref>). We applied this model to our expression data from the <inline-formula><mml:math id="inf77"><mml:mrow><mml:mn>0.625</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> treatment (since this concentration shows excellent concordance with the <inline-formula><mml:math id="inf78"><mml:mrow><mml:mn>1</mml:mn><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> data of Burridge et al., see <xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>) to obtain predicted log-odds of ACT. While these log-odds are unlikely to be well-calibrated due to differences in the training and test datasets, they may still accurately represent relative risk of ACT across our 45 individuals. Indeed, the log-odds correlated significantly with the troponin measurement slope (Spearman correlation <inline-formula><mml:math id="inf79"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math></inline-formula>, <xref ref-type="fig" rid="fig4">Figure 4f</xref>), suggesting our troponin measurements, and by extension our expression response data, recapitulate in vivo cellular response to doxorubicin.</p></sec><sec id="s2-5"><title>Cardiomyocyte molecular QTLs show enrichment in ACT GWAS</title><p>To determine the disease-relevance of our molecular QTLs we obtained summary statistics for the largest ACT GWAS to date (<xref ref-type="bibr" rid="bib47">Schneider et al., 2017</xref>). While this GWAS was not sufficiently powered to find genome-wide significant associations, 11 variants representing nine independent loci have <inline-formula><mml:math id="inf80"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, with the most significant (rs2184559) at <inline-formula><mml:math id="inf81"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>2.8</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. Of the 8 GWAS variants with <inline-formula><mml:math id="inf82"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> either tested in our eQTL mapping, or in high LD (<inline-formula><mml:math id="inf83"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>&gt;</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>) with a tested SNP, seven have a nominally significant marginal eQTL (<inline-formula><mml:math id="inf84"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>, the 8th has <inline-formula><mml:math id="inf85"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.07</mml:mn></mml:mrow></mml:math></inline-formula>) and four have a reQTL with <inline-formula><mml:math id="inf86"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula>. The one replicated variant in this GWAS, rs28714259, was not genotyped in our data but is in high LD (<inline-formula><mml:math id="inf87"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.98</mml:mn></mml:mrow></mml:math></inline-formula>) with rs11855704 which is a nominally significant marginal eQTL for tubulin gamma complex associated protein 5 (<italic>TUBGCP5</italic>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). rs4058287 (GWAS <inline-formula><mml:math id="inf88"><mml:mi>p</mml:mi></mml:math></inline-formula>-value <inline-formula><mml:math id="inf89"><mml:mrow><mml:mn>9.68</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>) has a marginal effect on Alpha-Protein Kinase 2 (<italic>ALPK2</italic>, also known as ‘Heart Alpha-Protein Kinase’ since it was discovered in mouse heart (<xref ref-type="bibr" rid="bib46">Ryazanov et al., 1999</xref>) and is expressed in few other tissues (<xref ref-type="bibr" rid="bib39">Melé et al., 2015</xref>)) expression (<inline-formula><mml:math id="inf90"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0016</mml:mn></mml:mrow></mml:math></inline-formula>) as well as a weak interaction effect (<inline-formula><mml:math id="inf91"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.06</mml:mn></mml:mrow></mml:math></inline-formula>, see <xref ref-type="fig" rid="fig5">Figure 5a</xref>). Interestingly, <italic>ALPK2</italic> has been shown to upregulate DNA repair genes and to enable caspase-3 cleavage and apoptosis in a colorectal cancer model (<xref ref-type="bibr" rid="bib62">Yoshida et al., 2012</xref>). The replicating variant from <xref ref-type="bibr" rid="bib2">Aminkeng et al., 2015</xref>, rs2229774 only occurs in two individuals in our cohort (who are heterozygous) making eQTL mapping infeasible. Additionally we find a marginal effect eQTL (<inline-formula><mml:math id="inf92"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0017</mml:mn></mml:mrow></mml:math></inline-formula>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>) on SLC28A3 for rs885004, which has previously been associated with ACT in a candidate gene study (<xref ref-type="bibr" rid="bib59">Visscher et al., 2013</xref>). rs885004 is intronic, is in LD (<inline-formula><mml:math id="inf93"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.98</mml:mn></mml:mrow></mml:math></inline-formula>) with another ACT implicated variant, rs7853758 (<xref ref-type="bibr" rid="bib58">Visscher et al., 2012</xref>), and falls in a DNase I hypersensitivity and H3K27ac peak present in numerous ENCODE cell lines (and is open in our ICs according to ATAC-seq data, see <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.33480.021</object-id><label>Figure 5.</label><caption><title>Cardiomyocyte molecular QTLs are enriched in meta-analyzed ACT GWAS (<xref ref-type="bibr" rid="bib47">Schneider et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Serie et al., 2017</xref>).</title><p>(<bold>a</bold>) rs4058287 has a GWAS <inline-formula><mml:math id="inf94"><mml:mi>p</mml:mi></mml:math></inline-formula>-value of <inline-formula><mml:math id="inf95"><mml:mrow><mml:mn>9.68</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and is a nominally significant eQTL (<inline-formula><mml:math id="inf96"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0016</mml:mn></mml:mrow></mml:math></inline-formula>) for <italic>ALPK2</italic>, which is down-regulated in response to doxorubicin. (<bold>b</bold>) SNPs that have a response eQTL with <inline-formula><mml:math id="inf97"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> are enriched in GWAS variants with <inline-formula><mml:math id="inf98"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula> (hypergeometric test <inline-formula><mml:math id="inf99"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>37</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>). (<bold>c</bold>) SNPs with a marginal or response splicing QTL at <inline-formula><mml:math id="inf100"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> show modest enrichment in GWAS <inline-formula><mml:math id="inf101"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.005</mml:mn></mml:mrow></mml:math></inline-formula> (hypergeometric <inline-formula><mml:math id="inf102"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math></inline-formula>).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig5-v2"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.022</object-id><label>Figure 5—figure supplement 1.</label><caption><title>SLC28A3 expression may mediate the association of rs885004 with ACT-sensitivity.</title><p>The intronic (to SLC28A3) variant rs885004, and the closely linked (<inline-formula><mml:math id="inf103"><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.98</mml:mn></mml:mrow></mml:math></inline-formula>) synonymous variant rs7853758, have been associated with ACT by candidate gene studies (<xref ref-type="bibr" rid="bib58">Visscher et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Visscher et al., 2013</xref>). We find rs885004, but not rs7853758, has a significant marginal effect on SLC28A3 expression.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig5-figsupp1-v2"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.023</object-id><label>Figure 5—figure supplement 2.</label><caption><title>rs885004 falls in an IC ATAC-seq peak. rs885004 (shown in red) falls in an ATAC-seq footprint in (unrelated) iPSC-derived cardiomyocytes (unpublished data).</title></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig5-figsupp2-v2"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.024</object-id><label>Figure 5—figure supplement 3.</label><caption><title>Enrichment of different classes of expression QTLs in ACT GWAS.</title><p>Enrichment of low (<inline-formula><mml:math id="inf104"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>) ACT GWAS <inline-formula><mml:math id="inf105"><mml:mi>p</mml:mi></mml:math></inline-formula>-values in different classes of expression QTLs (<inline-formula><mml:math id="inf106"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>). First three are GTEx tissues (steady-state). <bold>IC baseline:</bold> iPSC-derived cardiomyocytes at baseline (no doxorubicin). <bold>IC main effect:</bold> marginal effect of genotype across concentrations. <bold>IC combined:</bold> jointly testing for a main effect or interaction effect with concentration. <bold>IC either:</bold> either a marginal or response eQTL. <bold>IC response:</bold> testing for an interaction effect between genotype and concentration. <bold>IC response (AS):</bold> as for IC response but using both total and allele-specific expression to map reQTLs.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig5-figsupp3-v2"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.025</object-id><label>Figure 5—figure supplement 4.</label><caption><title>Enrichment of different classes of splicing QTLs in ACT GWAS.</title><p>Enrichment of low (<inline-formula><mml:math id="inf107"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></inline-formula>) ACT GWAS <inline-formula><mml:math id="inf108"><mml:mi>p</mml:mi></mml:math></inline-formula>-values in different classes of splicing QTLs (<inline-formula><mml:math id="inf109"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>). <bold>LCL:</bold> LeafCutter splicing QTLs mapped in the Yoruban LCLs (<xref ref-type="bibr" rid="bib32">Li et al., 2016</xref>). <bold>IC main effect:</bold> marginal effect of genotype across concentrations. <bold>IC combined:</bold> jointly testing for a main effect or interaction effect with concentration. <bold>IC either:</bold> either a marginal or response eQTL. <bold>IC response:</bold> testing for an interaction effect between genotype and concentration.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig5-figsupp4-v2"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.33480.026</object-id><label>Figure 5—figure supplement 5.</label><caption><title>Colocalization analysis.</title><p>Colocalization analysis for genes where the posterior probability of no association estimated by coloc is <inline-formula><mml:math id="inf110"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>0.75</mml:mn></mml:mrow></mml:math></inline-formula>.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-33480-fig5-figsupp5-v2"/></fig></fig-group><p>To determine whether our molecular QTLs are more useful than published QTLs for interpreting ACT risk variants we first sought to obtain the best powered GWAS data possible. Since the Schneider et al. GWAS was overall underpowered, we obtained additional ACT GWAS summary statistics from a more recent study (<xref ref-type="bibr" rid="bib49">Serie et al., 2017</xref>) and performed a meta-analysis with Schneider et al. We used this data to assess whether there was detectable enrichment of low GWAS <italic>p</italic>-values for our regulatory QTLs. When considering eQTL with nominal p<italic>&lt;</italic>10<sup>−5</sup> (corresponding approximately to 5% FDR) we found no enrichment for GWAS p<italic>&lt;</italic>0.05 for three GTEx tissues (heart, brain and lymphoblastoid cell lines—LCLs), our marginal effect eQTLs or baseline (no doxorubicin) only eQTLs (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). However, considering SNPs that are either main effect or response eQTL we see significant enrichment (one-sided hypergeometric p=6 × 10<sup>−20</sup>, OR = 1.40). Similarly for ‘combined’ eQTL where we explicitly test for any effect of genotype (main or interaction effect, see Methods) we see enrichment (p=5 × 10<sup>−12</sup>, OR = 1.29). Furthermore, focusing on response eQTL we see a stronger enrichment (p=2 × 10<sup>−37</sup>, OR = 1.95, <xref ref-type="fig" rid="fig5">Figure 5b</xref>), suggesting that the enrichment in combined eQTL is driven by this signal. Response eQTLs mapped using allelic-specific expression as well as total expression show the strongest enrichment (p=6 × 10<sup>−60</sup>, OR = 2.22). When considering splicing QTLs (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>) we found no enrichment for marginal sQTLs mapped in LCLs (<xref ref-type="bibr" rid="bib32">Li et al., 2016</xref>). Interestingly, in contrast to the total expression QTLs we found a significant enrichment (p=4 × 10<sup>−17</sup>, OR = 1.36, <xref ref-type="fig" rid="fig5">Figure 5c</xref>) for IC marginal sQTLs although the enrichment in response sQTLs was still higher in absolute terms (p=2 × 10<sup>−5</sup>, OR = 1.57). These findings are indicative that molecular response QTL mapping has potential for understanding the molecular basis of environmentally-dependent human disease.</p><p>Finally, we attempted colocalization analysis for our response eQTLs and meta-analyzed GWAS using <italic>coloc</italic> (<xref ref-type="bibr" rid="bib19">Giambartolomei et al., 2014</xref>), a Bayesian method based on summary statistics. For each region (gene in our case) <italic>coloc</italic> infers a posterior probability for each of five possibilities: (H0) no association, (H1) association for the eQTL only, (H2) association for the GWAS only, (H3) independent variants, or (H4) colocalization to one variant. Out of 43 genes with a SNP with a reQTL at p<italic>&lt;</italic>10<sup>−5</sup> and GWAS SNP at p<italic>&lt;</italic>0.05 <italic>coloc</italic> gave maximum posterior probability to the null hypothesis (H0, no association) for 32 genes, association only for reQTL (H1) for 9, and colocalization (H4) for one gene, <italic>NOL10</italic> (posterior probability of colocalization 0:54, <xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5</xref>, <xref ref-type="supplementary-material" rid="supp16">Supplementary file 16</xref>). While these results suggest our data is not sufficiently well-powered for colocalization analysis, we note that the posterior probability of colocalization (H4) is higher than that for independent signal (H3) in 40/43 tested genes.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Human iPSC-derived somatic cells provide a powerful, renewable and reproducible tool for modeling cellular responses to external perturbation in vitro, especially for non-blood cell-types such as cardiomyocytes which are extremely challenging to collect and even then are typically only available post-mortem. We established a sufficiently large iPSC panel to effectively query the transcriptomic response of differentiated cardiomyocytes to doxorubicin. We were also able to characterize the role of genetic variation in modulating this response, both in terms of total expression and alternative splicing. There are, of course, caveats associated with using an in vitro system, which may not accurately represent certain aspects cardiac response to doxorubicin in vivo. That said, the replication of GTEx heart eQTLs, association of troponin levels with predicted ACT-risk (<xref ref-type="bibr" rid="bib5">Burridge et al., 2016</xref>), and the observed GWAS enrichment, all support the notion that the IC system recapitulates substantial elements of in vivo biology. It is challenging to quantify this agreement, and there are in vivo factors that are certainly not represented. For example, excessive fibrosis may contribute to ACT (<xref ref-type="bibr" rid="bib9">Cascales et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Zhan et al., 2016</xref>; <xref ref-type="bibr" rid="bib15">Farhad et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Heck et al., 2017</xref>), although is unclear how substantial this contribution is as well as whether fibroblasts are directly activated by doxorubicin exposure or simply respond indirectly to cardiomyocyte damage. While our FACS analysis shows cardiomyocytes are the dominant cell type in our cultures, heterogeneity remains and other cell types could be mediating some of the observed changes.</p><p>For many diseases such as ACT which involve an environmental perturbation it is reasonable to suppose that eQTLs detected at steady-state are only tangentially relevant when attempting to interpret disease variants. Such concerns motivated us to focus on response eQTLs, that is, variants that that have functional consequences under specific cellular conditions because they interact, directly or indirectly, with the treatment. We used a statistical definition of reQTLs corresponding to cases where gene expression levels are significantly better explained using a model including an interaction term between genotype and treatment (represented as a categorical variable), compared to a model with only additive effects for genotype and treatment. Our characterization of the detected reQTL demonstrates that these variants are indeed candidate drivers of differences in individual transcriptomic response to doxorubicin. The strongest reQTL effects correspond to completely different response patterns for the major and minor alleles, while weaker effects correspond to more subtle modulation of the same response pattern. We note that it is not necessarily the case that such reQTLs are the only functionally relevant eQTLs. eSNPs with a marginal (additive) effect on expression of a gene responsive to doxorubicin (as most genes are) could still be important if the relationship between expression and ACT-risk is nonlinear, for example involving thresholding effects.</p><p>We observed a statistical enrichment of expression and (to a lesser extent) splicing QTLs in ACT GWAS. However, with no reproducible genome-wide significant associations available, fine-mapping of causal variants remains fraught. We anticipate our findings will be increasingly valuable as larger-scale ACT GWAS become available.</p><p>We derived ICs from healthy individuals so we do not known which individuals would develop ACT if they required anthracycline treatment. Mapping molecular response QTLs in larger panels of ICs from patients treated with anthracyclines who do or do not develop ACT symptoms would allow stronger conclusions to be drawn about the contribution of the detected (r)eQTLs to disease etiology.</p><p>We used a panel of Hutterites individual since this homogeneous population offers unique advantages for mapping genetic traits: exposure to a fairly uniform environment and less variable genetic background, despite still representing much of European diversity (<xref ref-type="bibr" rid="bib41">Newman et al., 2004</xref>). However, the genetic basis of ACT susceptibility is likely complex and some relevant genetic variation may not be well represented in this cohort.</p><p>Finally, an interesting observation in our study is that splicing fidelity is reduced upon doxorubicin exposure. This is not completely unexpected since a key downstream side-effect of doxorubicin is increased oxidative stress, which has been previously associated with dysregulated splicing of specific genes (<xref ref-type="bibr" rid="bib12">Disher and Skandalis, 2007</xref>; <xref ref-type="bibr" rid="bib48">Seo et al., 2016</xref>). Our finding that this effect is prevalent across the transcriptome poses further questions about what known effects of doxorubicin might, in fact, be mediated by changes in RNA splicing.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Sample collection and genotyping</title><p>Generation of lymphoblastoid cell lines (LCLs) and genome-wide genotyping of many individuals from a multi-generational pedigree were performed previously. Briefly, lymphocytes were isolated from whole blood samples using Ficoll-Paque and immortalized using Epstein Barr Virus (EBV) (<xref ref-type="bibr" rid="bib10">Cusanovich et al., 2012</xref>; <xref ref-type="bibr" rid="bib11">Cusanovich et al., 2016</xref>). Phased genotypes were obtained by combining pedigree information, genotypes from SNP arrays, and genotypes from whole genome sequencing of related individuals (<xref ref-type="bibr" rid="bib35">Livne et al., 2015</xref>).</p></sec><sec id="s4-2"><title>iPSC reprogramming</title><p>We reprogrammed 75 LCLs to iPSCs using episomal plasmid vectors, containing <italic>OCT3/4</italic>, <italic>p53</italic> shRNA, <italic>SOX2</italic>, <italic>KLF4</italic>, <italic>L-MYC</italic>, and <italic>LIN28</italic> which avoids integrating additional transgenes (<xref ref-type="bibr" rid="bib42">Okita et al., 2011</xref>). Initially, the lines were generated on mouse embryonic fibroblasts (MEF), which coated the well and served as feeder cells to create an environment supportive of pluripotent stem cells. The colony was then mechanically passaged on MEF and tested for expression of pluripotency-associated markers by immunofluorescence staining and RT-PCR. The lines were passaged for at least 10 weeks on MEF to ensure lines had stabilized.</p><p>All iPSC lines were characterized as described previously (<xref ref-type="bibr" rid="bib17">Gallego Romero et al., 2015</xref>). Briefly, we initially performed qPCR using 1μg of total RNA, converted to cDNA, from all samples to confirm the endogenous expression of pluripotency genes: <italic>OCT3/4</italic>, <italic>NANOG</italic>, and <italic>SOX2</italic> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). We next confirmed pluripotency using PluriTest (<xref ref-type="bibr" rid="bib40">Müller et al., 2011</xref>). All samples were classified as pluripotent and had a low novelty score (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Additionally, we confirmed the ability of all iPSC lines to differentiate into the three main germ layers using the embryoid body (EB) assay (Supplementary Data). Finally, we tested for the presence and expression of the EBV gene EBNA-1 using PCR (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). We tested all samples for both genomic integrations and vector-based EBV. If the cells were positive (two positive and one indeterminate case was identified), we further tested the origin of the EBV (genomic or episomal) using primers specific to the LMP-2A gene found in EBV or part of the sequence specific to the episomal plasmid (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). We concluded that two lines still had EBV present in the genome, this was also reflected in EBNA-1 gene expression for these individuals (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). We retained these individuals because they passed all quality control metrics and were not outliers based on genome-wide gene expression. It should also be noted that gene expression levels are extremely similar between iPSC lines. This relative homogeneity further demonstrates the quality of our iPSC lines. In summary, all iPSC lines showed expression of pluripotent genes quanti1ed by qPCR, generated EBs for all three germ layers, and were classified as pluripotent based on PluriTest.</p></sec><sec id="s4-3"><title>Cardiomyocyte differentiation</title><p>iPSC lines were transitioned to feeder-free conditions, which was necessary to prime the iPSCs for differentiation. Next we differentiated the iPSCs to cardiomyocytes (<xref ref-type="bibr" rid="bib33">Lian et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Burridge et al., 2014</xref>). iPSC lines were covered with a 1:60 dilution matrigel overlay for 24 hr. On day 0 iPSC lines were treated with 12<inline-formula><mml:math id="inf111"><mml:mi>μ</mml:mi></mml:math></inline-formula>M of the <italic>GSK3</italic> inhibitor, CHIR99021, in RPMI+ B27 medium (RPMI1640, 2 nM L-glutamine and 1x B27 supplement minus insulin) for 24 hr at which time media was replaced with fresh RPMI + B27. 72 hr after the addition of CHIR99021 (Day 3), 2<inline-formula><mml:math id="inf112"><mml:mi>μ</mml:mi></mml:math></inline-formula>M of the Wnt inhibitor Wnt C-59 was added for 48 hr. Fresh RPMI + B27 was added on Days 5, 7 and 10. Beating cells appeared between Days 8–10. These cardiomyocytes consisted of ventricular, atrial and pacemaker-like cells. The cells formed thick layers and contract throughout the well. Metabolic selection was used to purify the cardiomyocytes (<xref ref-type="bibr" rid="bib54">Tohyama et al., 2013</xref>) from Day 14 to Day 20 when glucose-free RPMI media supplemented with the components essential for cardiomyocyte differentiation (<xref ref-type="bibr" rid="bib6">Burridge et al., 2014</xref>), ascorbic acid and human serum albumin, together with lactate, a substrate uniquely metabolized by cardiomyocytes, was added to cells. Because this lactate media can only be metabolized by cardiomyocytes, the non-cardiomyocytes in the culture were removed over the 6 day treatment. On day 20 the cardiomyocytes, now at a high cTnT purity, were replated for experiments in media that contains only galactose and fatty acids as an energy source. This galactose media forces the cardiomyocytes to undergo aerobic respiration, rather than anaerobic glycolysis common in cultured cells.</p></sec><sec id="s4-4"><title>IC purity analysis</title><p>At day 20 when ICs were plated for doxorubicin exposure, a portion of cells were collected to assess purity. Cells were harvested from plates by incubating with TrypLE Express (Thermo Fisher Scientific, Cat. No 12604013) for 5 min at 37°C. Once removed, cells were manually dissociated further by passing through a 100<inline-formula><mml:math id="inf113"><mml:mi>μ</mml:mi></mml:math></inline-formula>m and then 40<inline-formula><mml:math id="inf114"><mml:mi>μ</mml:mi></mml:math></inline-formula>m strainer to create a single cell suspension. Cells were then resuspended, fixed, and permeabilized (<italic>Foxp3</italic>/Transcription Factor Staining Buffer Set; eBioscience/Affymetrix, Cat. No 00-5523-00) according to the manufacturer’s instructions. Cells were stained with directly conjugated antibodies to cTnI (Alexa Fluor647 Mouse Anti-Cardiac Troponin I Clone C5; BD Biosciences, Cat. No 564409) and cTnT (PE Mouse Anti-Cardiac Troponin T Clone 13–11; BD Biosciences, Cat. No 564767). The Zombie Violet<sup>TM</sup> Fixable Viability Kit (BioLegend, Cat. No 423113) was used to assess cell viability at the time of fixation. The following isotype controls were used: Alexa Fluor647 Mouse IgG2b, <inline-formula><mml:math id="inf115"><mml:mi>κ</mml:mi></mml:math></inline-formula> Isotype Control Clone 27–35 (BD Biosciences Catalog No. 558713) and PE Mouse IgG1, <inline-formula><mml:math id="inf116"><mml:mi>κ</mml:mi></mml:math></inline-formula> Isotype Control Clone MOPC-21 (BD Biosciences Catalog No. 554680). Cells were analyzed using a FACS Canto or LSR-II flow cytometers (BD Biosciences), and the data were analyzed with FlowJo software (v10.0.7, Tree Star). All gates were established such that &lt;2% of cells stained with isotype controls were positive and dead cells were excluded.</p></sec><sec id="s4-5"><title>Doxorubicin exposure</title><p>We incubated the cardiomyocytes in 0, 0.625, 1.25, 2.5, or 5 <inline-formula><mml:math id="inf117"><mml:mi>μ</mml:mi></mml:math></inline-formula>M doxorubicin. After 24 hr, we collected the serum and cells from each condition. From the serum, we measured cardiac Troponin T levels using the ABNOVA Troponin I (Human) ELISA kit (cat. no. KA0233). From the cells, we extracted RNA for sequencing. Cells from each individual were treated separately, but batches of experiments were performed on different days. Each treatment batch contained 1 to 4 individuals. RNA quality was assessed with the Agilent Bioanalyzer.</p></sec><sec id="s4-6"><title>RNA-sequencing</title><p>We prepared libraries using the Illumina TruSeq Library Kit and generated 50 bp single-end reads on a HiSeq 4000 at the University of Chicago Functional Genomics Facility. We confirmed sequencing quality using FastQC and MultiQC (<xref ref-type="bibr" rid="bib14">Ewels et al., 2016</xref>). We confirmed sample identity by (1) comparing allelic counts (quantified using samtools mpileup [<xref ref-type="bibr" rid="bib30">Li et al., 2009</xref>]) of exonic SNPs to the known genotypes and (2) running verifyBamID (<xref ref-type="bibr" rid="bib24">Jun et al., 2012</xref>).</p></sec><sec id="s4-7"><title>Expression quantification</title><p>We aligned RNA-seq reads using STAR version 2.5.2a (<xref ref-type="bibr" rid="bib13">Dobin et al., 2013</xref>) to GRCh38/GENCODE release 24. We counted reads using feature Counts (<xref ref-type="bibr" rid="bib34">Liao et al., 2014</xref>) and calculated counts per million reads (cpm) using `cpm` from the `edgeR` ‘R package (version 3.18.1) (<xref ref-type="bibr" rid="bib45">Robinson et al., 2010</xref>). We discarded samples with <inline-formula><mml:math id="inf118"><mml:mrow><mml:mo>&lt;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>7</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> exonic reads and genes with median <inline-formula><mml:math id="inf119"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>log</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mi>p</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> less than <inline-formula><mml:math id="inf120"><mml:mn>0</mml:mn></mml:math></inline-formula>0.</p></sec><sec id="s4-8"><title>Differential expression analysis</title><p>We performed differential expression (DE) analysis across all five doxorubicin concentrations jointly, using either a linear model on quantile normalized cpm value or Spearman correlation, followed by Benjamini-Hochberg False Discovery Rate (FDR) control. Since the vast majority of genes showed differential expression we did not investigate better powered DE methods such as DESeq2.</p><p>We clustered genes into ‘response patterns’ using a <inline-formula><mml:math id="inf121"><mml:mi>K</mml:mi></mml:math></inline-formula>-component mixture model<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="right left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mi>π</mml:mi></mml:mtd><mml:mtd><mml:mo>∼</mml:mo><mml:mtext>Dir</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>K</mml:mi><mml:mo>,</mml:mo><mml:mo>⋯</mml:mo><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>π</mml:mi></mml:mtd><mml:mtd><mml:mo>∼</mml:mo><mml:mtext>Discrete</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>π</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi></mml:mtd><mml:mtd><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf122"><mml:mi>π</mml:mi></mml:math></inline-formula> is a prior probability vector over cluster assignments, Dir is the Dirichlet distribution, <inline-formula><mml:math id="inf123"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is cluster from which gene <inline-formula><mml:math id="inf124"><mml:mi>g</mml:mi></mml:math></inline-formula> is generated, <inline-formula><mml:math id="inf125"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the expression of gene <inline-formula><mml:math id="inf126"><mml:mi>g</mml:mi></mml:math></inline-formula> in individual <inline-formula><mml:math id="inf127"><mml:mi>n</mml:mi></mml:math></inline-formula> at concentration <inline-formula><mml:math id="inf128"><mml:mi>c</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf129"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the mixture parameter (mean) across concentrations for cluster <inline-formula><mml:math id="inf130"><mml:mi>k</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="inf131"><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> is a shared noise variance. We marginalize (sum) over <inline-formula><mml:math id="inf132"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and optimize with respect to <inline-formula><mml:math id="inf133"><mml:mrow><mml:mi>π</mml:mi><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo>,</mml:mo><mml:mi>σ</mml:mi></mml:mrow></mml:math></inline-formula> using the rstan R package (<xref ref-type="bibr" rid="bib8">Carpenter et al., 2016</xref>) (version 2.16.2). The hyperparameters of the Dirichlet distribution are set such that in the limit of large <inline-formula><mml:math id="inf134"><mml:mi>K</mml:mi></mml:math></inline-formula> the model approximates a Dirichlet process mixture (<xref ref-type="bibr" rid="bib37">MacEachern and Müller, 1998</xref>) which automatically learns of an appropriate number of mixture components to use from data.</p><p>Gene set and promoter motif enrichment were performed using HOMER v4.9.1 (<xref ref-type="bibr" rid="bib23">Heinz et al., 2010</xref>) using default parameters and without de novo motif search.</p></sec><sec id="s4-9"><title>Response eQTL mapping</title><p>We developed an extension of the PANAMA (<xref ref-type="bibr" rid="bib16">Fusi et al., 2012</xref>) linear mixed model (LMM) framework to map eQTLs and response eQTLs while accounting for latent confounding, which we call suez. suez entails a two step procedure. Step one is used to learn latent factors from all genes, using the model<disp-formula id="equ2"><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="right left right left right left right left right left right left" columnspacing="0em 2em 0em 2em 0em 2em 0em 2em 0em 2em 0em" displaystyle="true" rowspacing="3pt"><mml:mtr><mml:mtd><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mi/><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ξ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mi/><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mspace width="2em"/><mml:mrow><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mtext> </mml:mtext><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>a</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mi/><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mspace width="2em"/><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mtext> </mml:mtext><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mtext> </mml:mtext><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>ξ</mml:mi></mml:mtd><mml:mtd><mml:mi/><mml:mo>∼</mml:mo><mml:mi>M</mml:mi><mml:mi>V</mml:mi><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ξ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi mathvariant="normal">Σ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="2em"/><mml:mrow><mml:mi>k</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>p</mml:mi><mml:mtext> </mml:mtext><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mtext> </mml:mtext><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>ϵ</mml:mi></mml:mtd><mml:mtd><mml:mi/><mml:mo>∼</mml:mo><mml:mi>M</mml:mi><mml:mi>V</mml:mi><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mtext>diag</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ϵ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mspace width="2em"/><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf135"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are latent factors, <inline-formula><mml:math id="inf136"><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are per gene, per concentration fixed effects. We integrate over <inline-formula><mml:math id="inf137"><mml:mrow><mml:mi>W</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>ξ</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf138"><mml:mi>ϵ</mml:mi></mml:math></inline-formula>, which results in a per gene multivariate normal,<disp-formula id="equ3"><label>(2)</label><mml:math id="m3"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo>:</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi>M</mml:mi><mml:mi>V</mml:mi><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>V</mml:mi><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mo>:</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder></mml:mstyle><mml:mtext> </mml:mtext><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mo>:</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>:</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>U</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ξ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>Σ</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>I</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="inf139"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo>:</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> refers to the vector of expression for gene <inline-formula><mml:math id="inf140"><mml:mi>g</mml:mi></mml:math></inline-formula> across all individuals and concentrations (i.e. all ‘samples’ where a sample is an individual-concentration pair), <inline-formula><mml:math id="inf141"><mml:mi>V</mml:mi></mml:math></inline-formula> is a matrix mapping concentrations to samples (i.e. <inline-formula><mml:math id="inf142"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> iff sample <inline-formula><mml:math id="inf143"><mml:mi>s</mml:mi></mml:math></inline-formula> is at concentration <inline-formula><mml:math id="inf144"><mml:mi>c</mml:mi></mml:math></inline-formula>) and <inline-formula><mml:math id="inf145"><mml:mi>U</mml:mi></mml:math></inline-formula> is a matrix of which samples are for the same individual (i.e. <inline-formula><mml:math id="inf146"><mml:mrow><mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:msup><mml:mi>s</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> if sample <inline-formula><mml:math id="inf147"><mml:mi>s</mml:mi></mml:math></inline-formula> and sample <inline-formula><mml:math id="inf148"><mml:msup><mml:mi>s</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:math></inline-formula> come from the same individual). We optimize <inline-formula><mml:math id="inf149"><mml:mrow><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:math></inline-formula> and the variances <inline-formula><mml:math id="inf150"><mml:mrow><mml:mo>{</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ξ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ϵ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula> jointly across all genes <inline-formula><mml:math id="inf151"><mml:mi>g</mml:mi></mml:math></inline-formula>.</p><p>In step 2 we test individual gene-SNP pairs while accounting for confounding using the covariance matrix<disp-formula id="equ4"><label>(3)</label><mml:math id="m4"><mml:mrow><mml:msub><mml:mi>Σ</mml:mi><mml:mi>π</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder></mml:mstyle><mml:mtext> </mml:mtext><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mo>:</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>:</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>u</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>U</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ξ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>Σ</mml:mi></mml:mrow></mml:math></disp-formula>which includes both latent confounding, individual random effects and similarity due to kinship. We consider three LMMs, all with the same parameterization of the covariance <inline-formula><mml:math id="inf152"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>π</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>Σ</mml:mi><mml:mi>π</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>I</mml:mi></mml:mrow></mml:math></inline-formula> where <inline-formula><mml:math id="inf153"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>π</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf154"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> are optimized along with the fixed effects to allow the extent to which each gene follows the global covariance pattern to be adapted. The simple structure of this covariance also allows pre-computation of the eigen-decomposition of <inline-formula><mml:math id="inf155"><mml:mrow><mml:msub><mml:mi>Σ</mml:mi><mml:mi>π</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> which enables linear (rather than cubic) time evaluation of the likelihood and its gradient.</p><p>Model 0 involves no effect of the SNP (and can therefore be fit once for a gene) and a fixed effect for concentration. Model 1 adds a marginal effect of the SNP genotype dosage <inline-formula><mml:math id="inf156"><mml:mi>d</mml:mi></mml:math></inline-formula>. Finally model 2 adds an interaction effect between concentration and genotype, which is equivalent to a concentration-specific genotype effect. In summary:<disp-formula id="equ5"><label>(4)</label><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>Model </mml:mtext><mml:mn>0</mml:mn><mml:mo>:</mml:mo><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ6"><label>(5)</label><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>Model </mml:mtext><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ7"><label>(6)</label><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>Model </mml:mtext><mml:mn>2</mml:mn><mml:mo>:</mml:mo><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>We optimize <inline-formula><mml:math id="inf157"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>π</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf158"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> and the regression coefficients for each of the three models separately, and use likelihood ratio tests (LRT) to compare the models. Comparing Model 1 vs 0 (one degree of freedom) tests whether there is a marginal effect of the variant. Comparing Model 2 vs 1 (<inline-formula><mml:math id="inf159"><mml:mrow><mml:mi>C</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> degrees of freedom, where <inline-formula><mml:math id="inf160"><mml:mi>C</mml:mi></mml:math></inline-formula> is the number of conditions/concentrations) tests whether there is an interaction effect, i.e. whether the genetic effect on expression is different at different concentrations (or equivalently whether the response to doxorubicin is different for different genotypes). Finally Model 2 vs 0 (<inline-formula><mml:math id="inf161"><mml:mrow><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula> degrees of freedom) tests whether there is any effect of genotype on expression, either in terms of a marginal or concentration-specific effect (we refer to these as ‘combined’ eQTL). We use the conservative approach of using Bonferroni correction across SNPs for a gene, followed by Benjamini-Hochberg FDR control.</p><p>We quantile normalize the expression levels across all samples for each gene to a standard normal distribution so that the distributional assumptions of our linear mixed model are reasonable. However, optimizing the variance parameters <inline-formula><mml:math id="inf162"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>π</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf163"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> means that the <inline-formula><mml:math id="inf164"><mml:mrow><mml:msup><mml:mi>χ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> distribution for the LRT will only hold asymptotically and <inline-formula><mml:math id="inf165"><mml:mi>p</mml:mi></mml:math></inline-formula>-values for finite sample sizes will tend to be somewhat anti-conservative. To account for this for response-eQTLs, we use a parametric bootstrap since there is no fully valid permutation strategy for testing interaction effects. This involves first fitting Model 1 and then simulating new expression data under the fitted model. Models 1 and 2 are then (re)fit to this data and compared using an LRT. We then perform Bonferroni correction across SNPs for each gene to obtain an empirical null distribution of per gene <inline-formula><mml:math id="inf166"><mml:mi>p</mml:mi></mml:math></inline-formula>-values which we use to estimate the true FDR for our response-eQTL results.</p><p>For significant reQTLs we assigned the response of the minor allele and major allele to the previously determined clusters using the model<disp-formula id="equ8"><mml:math id="m8"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:malignmark/><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:msub><mml:mi>z</mml:mi><mml:mi>A</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:msub><mml:mi>z</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="inf167"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the expression for individual <inline-formula><mml:math id="inf168"><mml:mi>n</mml:mi></mml:math></inline-formula> at concentration <inline-formula><mml:math id="inf169"><mml:mi>c</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf170"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>A</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf171"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> are the cluster assignments for the major and minor allele respectively, <inline-formula><mml:math id="inf172"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula> is the genotype dosage, and <inline-formula><mml:math id="inf173"><mml:mi>θ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf174"><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> are fixed at the values learned in Equation 1. For each reQTL separately we calculate the likelihood of <inline-formula><mml:math id="inf175"><mml:mi>y</mml:mi></mml:math></inline-formula> given all possible pairs of assignments <inline-formula><mml:math id="inf176"><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> and choose the maximum likelihood solution.</p><p>As for all <inline-formula><mml:math id="inf177"><mml:mi>k</mml:mi></mml:math></inline-formula>-means clustering in the paper, we used KMeans_rcpp function of the R package ClusterR v1.0.6, taking the best of 10 initializations using the k-means++ option, to cluster the normalized genotype effect profiles of the significant associations. The choice of 9 clusters was determined manually.</p></sec><sec id="s4-10"><title>Using allelic expression</title><p>We (<xref ref-type="bibr" rid="bib27">Knowles et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">van de Geijn et al., 2015</xref>) and others (<xref ref-type="bibr" rid="bib29">Kumasaka et al., 2016</xref>) have demonstrated that modeling allele-specific expression can improve power to detect both <italic>cis</italic> eQTLs (<xref ref-type="bibr" rid="bib56">van de Geijn et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Kumasaka et al., 2016</xref>) and reQTLs (<xref ref-type="bibr" rid="bib27">Knowles et al., 2017</xref>). Here we employ a combination of ideas from these methods:</p><list list-type="bullet"><list-item><p>We assume our computational phasing between the regulatory and exonic SNP(s) is correct, since we have previously shown that errors in phasing reduce power but do not inflate false positives (<xref ref-type="bibr" rid="bib56">van de Geijn et al., 2015</xref>).</p></list-item><list-item><p>We use a beta-binomial (denoted <inline-formula><mml:math id="inf178"><mml:mrow><mml:mi>B</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:math></inline-formula>) likelihood allowing exact likelihood calculations and straightforward maximum likelihood parameter estimation via LBFGS in Stan (<xref ref-type="bibr" rid="bib8">Carpenter et al., 2016</xref>). We use the parametrization <inline-formula><mml:math id="inf179"><mml:mrow><mml:mi>B</mml:mi><mml:mi>B</mml:mi><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> where <inline-formula><mml:math id="inf180"><mml:mi>n</mml:mi></mml:math></inline-formula> is the total count, <inline-formula><mml:math id="inf181"><mml:mi>p</mml:mi></mml:math></inline-formula> is the mean, and <inline-formula><mml:math id="inf182"><mml:mi>c</mml:mi></mml:math></inline-formula> is the concentration. The usual pseudo-count parametrization is recovered as <inline-formula><mml:math id="inf183"><mml:mrow><mml:mi>a</mml:mi><mml:mo>=</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:math></inline-formula>.</p></list-item><list-item><p>We model multiple exonic SNPs per gene to ease integration with the total expression signal from suez.</p></list-item></list><p>Under the hypothesis that the allelic effect of the test regulatory SNP varies across concentrations (analogous to Model 2 in <xref ref-type="disp-formula" rid="equ7">Equation 6</xref>), we have<disp-formula id="equ9"><label>(7)</label><mml:math id="m9"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi>B</mml:mi><mml:mi>B</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>σ</mml:mi><mml:mo>(</mml:mo><mml:mi>μ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:math></disp-formula>where there are <inline-formula><mml:math id="inf184"><mml:mi>K</mml:mi></mml:math></inline-formula> exonic SNPs in a gene, with alternative allele counts <inline-formula><mml:math id="inf185"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and read coverage <inline-formula><mml:math id="inf186"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. <inline-formula><mml:math id="inf187"><mml:mi>σ</mml:mi></mml:math></inline-formula> is the logistic function. <inline-formula><mml:math id="inf188"><mml:mi>μ</mml:mi></mml:math></inline-formula> is an intercept term to account for reference mapping bias, and <inline-formula><mml:math id="inf189"><mml:mi>γ</mml:mi></mml:math></inline-formula> is a per-gene concentration (reciprocal of over dispersion) parameter. We regularize <inline-formula><mml:math id="inf190"><mml:mi>γ</mml:mi></mml:math></inline-formula> using a <inline-formula><mml:math id="inf191"><mml:mrow><mml:mi>Γ</mml:mi><mml:mo>(</mml:mo><mml:mn>1.001</mml:mn><mml:mo>,</mml:mo><mml:mn>0.001</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> prior. <inline-formula><mml:math id="inf192"><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula> is the phased heterozygosity of the test regulatory SNP in individual <inline-formula><mml:math id="inf193"><mml:mi>n</mml:mi></mml:math></inline-formula>, with <inline-formula><mml:math id="inf194"><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> if the regulatory SNP is homozygous (these individuals are included to help estimate <inline-formula><mml:math id="inf195"><mml:mi>μ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf196"><mml:mi>c</mml:mi></mml:math></inline-formula>) and <inline-formula><mml:math id="inf197"><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> or <inline-formula><mml:math id="inf198"><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> if the regulatory SNP is heterozygous and in phase (1) or opposite phase (-1) with SNP <inline-formula><mml:math id="inf199"><mml:mi>k</mml:mi></mml:math></inline-formula>. <inline-formula><mml:math id="inf200"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is the effect size in concentration <inline-formula><mml:math id="inf201"><mml:mi>c</mml:mi></mml:math></inline-formula>. The null (no interaction effect, corresponding to Model 1 in <xref ref-type="disp-formula" rid="equ7">Equation 6</xref>) is that <inline-formula><mml:math id="inf202"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> for all all <inline-formula><mml:math id="inf203"><mml:mi>c</mml:mi></mml:math></inline-formula>.</p><p>To integrate evidence from total and allelic specific expression it is valid to add the log likelihood ratios, which can be seen as either fitting one model with likelihood terms for the two components, or as a result of <inline-formula><mml:math id="inf204"><mml:mrow><mml:msup><mml:mi>χ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> random variables being closed under addition. This approach has substantially better power than applying Fisher’s combined probability test to <inline-formula><mml:math id="inf205"><mml:mi>p</mml:mi></mml:math></inline-formula>-values from testing the total and allelic expression components separately. Twice the summed log likelihood ratio is asymptotically <inline-formula><mml:math id="inf206"><mml:mrow><mml:msup><mml:mi>χ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> with degrees of freedom being simply the sum of the degrees of freedom of the two components (so usually <inline-formula><mml:math id="inf207"><mml:mrow><mml:mn>4</mml:mn><mml:mo>+</mml:mo><mml:mn>4</mml:mn><mml:mo>=</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:math></inline-formula> in our case). In practice we only fit the total expression model if there are at least <inline-formula><mml:math id="inf208"><mml:mn>5</mml:mn></mml:math></inline-formula> alternative alleles observed for the test regulatory SNP, and only fit the allele-specific model if there are at least <inline-formula><mml:math id="inf209"><mml:mrow><mml:mn>2000</mml:mn></mml:mrow></mml:math></inline-formula> supporting allelic reads for the gene, so some regulatory SNPs are only tested using one component or the other. In addition, for some genes whose expression is very low for specific concentrations there may be no allelic reads for a concentration, in which case the degrees of freedom for the allele-specific component will be reduced since no <inline-formula><mml:math id="inf210"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is learned for that concentration.</p></sec><sec id="s4-11"><title>Assessing agreement with GTEx eQTLs</title><p>We initially compared our eQTLs to GTEx eQTLs by estimating Storey’s π<sub>1</sub> (<xref ref-type="bibr" rid="bib50">Storey and Tibshirani, 2003</xref>), using the q value R package v2.8.0, for GTEx nominal <italic>p</italic>-values for our significant eQTLs (at a nominal p<italic>&lt;</italic>10<sup>−5</sup>). While the GTEx heart tissues show higher replication than most tissues, surprising tissues ranked higher (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). We reasoned that differential power across the GTEx tissues due to differing sample size and noise levels confound this simple approach. We therefore used an extension of Storey’s π<sub>1</sub> to test for overlap between two sets of <italic>p</italic>-values. For each GTEx tissue we fit (using LBFGS in Stan) a mixture model<disp-formula id="equ10"><label>(8)</label><mml:math id="m10"><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>∼</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>00</mml:mn></mml:mrow></mml:msub><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mi>B</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mi>B</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mi>B</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>)</mml:mo><mml:mi>B</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="inf211"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the <inline-formula><mml:math id="inf212"><mml:mi>p</mml:mi></mml:math></inline-formula>-value for SNP-gene pair <inline-formula><mml:math id="inf213"><mml:mi>i</mml:mi></mml:math></inline-formula> in tissue <inline-formula><mml:math id="inf214"><mml:mi>j</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf215"><mml:mi>U</mml:mi></mml:math></inline-formula> is the uniform distribution on <inline-formula><mml:math id="inf216"><mml:mrow><mml:mo>[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>]</mml:mo></mml:mrow></mml:math></inline-formula> (corresponding to <inline-formula><mml:math id="inf217"><mml:mi>p</mml:mi></mml:math></inline-formula>-values coming from the null) and <inline-formula><mml:math id="inf218"><mml:mi>B</mml:mi></mml:math></inline-formula> is the beta distribution (corresponding to non-null <inline-formula><mml:math id="inf219"><mml:mi>p</mml:mi></mml:math></inline-formula>-values).<inline-formula><mml:math id="inf220"><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>00</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> correspond to mixture weights are estimates of the proportion of SNP-gene pairs that are (a) null for both tissues, (b) null for tissue one and non-null for tissue 2, (c) non-null for tissue one and null for tissue 2, (d)non-null for both tissues. Note that <inline-formula><mml:math id="inf221"><mml:mi>π</mml:mi></mml:math></inline-formula> sums to <inline-formula><mml:math id="inf222"><mml:mn>1</mml:mn></mml:math></inline-formula>. We constrain the hyperparameters <inline-formula><mml:math id="inf223"><mml:mrow><mml:msub><mml:mi>a</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>∈</mml:mo><mml:mo>[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>]</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf224"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> to encode the assumption that non-null SNP-gene pairs should have low <inline-formula><mml:math id="inf225"><mml:mi>p</mml:mi></mml:math></inline-formula>-values. Due to the large number of SNP-gene pairs tested, in practice we bin <inline-formula><mml:math id="inf226"><mml:mi>p</mml:mi></mml:math></inline-formula>-values on a regular <inline-formula><mml:math id="inf227"><mml:mrow><mml:mn>100</mml:mn><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></inline-formula> grid and use the bin counts to weight the likelihood. Finally we estimate the mutual information between the pair of tissues as:<disp-formula id="equ11"><label>(9)</label><mml:math id="m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>M</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:munder><mml:mtext> </mml:mtext><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:munder><mml:mtext> </mml:mtext><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mfrac><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>π</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf228"><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>}</mml:mo></mml:mrow></mml:msub></mml:mstyle><mml:mtext> </mml:mtext><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf229"><mml:mrow><mml:msub><mml:mstyle displaystyle="true" mathsize="140%"><mml:msup><mml:mi>π</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mstyle><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>}</mml:mo></mml:mrow></mml:msub></mml:mstyle><mml:mtext> </mml:mtext><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are marginal probabilities. This approach explicitly estimates the proportion of null tests in tissue 1 (<inline-formula><mml:math id="inf230"><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>) and tissue 2 (<inline-formula><mml:math id="inf231"><mml:mrow><mml:msub><mml:mstyle displaystyle="true" mathsize="140%"><mml:msup><mml:mi>π</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>) as well as the proportion of tests that are non-null in both (<inline-formula><mml:math id="inf232"><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>). This approach both controls for power in both tissues and negates the need to choose arbitrary significance thresholds.</p></sec><sec id="s4-12"><title>Splicing analysis</title><p>We ran LeafCutter v0.2.6_dev (using default settings) which allows joint differential intron excision testing across more than two conditions. For each Alternative Splicing Cluster (ASC) LeafCutter fits a set of <inline-formula><mml:math id="inf233"><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>S</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> probability vectors <inline-formula><mml:math id="inf234"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, across detected splice junctions <inline-formula><mml:math id="inf235"><mml:mi>i</mml:mi></mml:math></inline-formula>, at each concentration <inline-formula><mml:math id="inf236"><mml:mi>c</mml:mi></mml:math></inline-formula>. For ASCs determined to be significantly (5% FDR) differential spliced across concentrations, we calculated the entropy <inline-formula><mml:math id="inf237"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:mtext> </mml:mtext><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> at each concentration <inline-formula><mml:math id="inf238"><mml:mi>c</mml:mi></mml:math></inline-formula>. We normalized these profiles as <inline-formula><mml:math id="inf239"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> and clustered these profiles, using KMeans_rcpp as above.</p><p>To investigate the relative usage of cryptic splice sites we first determined the set of 7792 splice junctions that (a) fell in ASCs determined to be significantly differentially spliced (5% FDR) and (b) had <inline-formula><mml:math id="inf240"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:munder><mml:mo form="prefix" movablelimits="true">max</mml:mo><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:munder><mml:mo form="prefix" movablelimits="true">min</mml:mo><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. We obtained normalized intron excision rates by subtracting the per intron mean and dividing by the per intron standard deviation. These <inline-formula><mml:math id="inf241"><mml:mi>ψ</mml:mi></mml:math></inline-formula> profiles were clustered using KMeans_rcpp. Cryptic splice site usage was determined by considering all exons in Gencode v26 and ignoring transcript structure (i.e. a junction spanning two splice sites used but only in different transcripts would still be considered ‘annotated’).</p><p>For (response) splicing QTL we calculated within ASC intron excision <inline-formula><mml:math id="inf242"><mml:mi>ψ</mml:mi></mml:math></inline-formula> with pseudocount of <inline-formula><mml:math id="inf243"><mml:mrow><mml:mn>0.5</mml:mn></mml:mrow></mml:math></inline-formula>, and set entries with <inline-formula><mml:math id="inf244"><mml:mn>0</mml:mn></mml:math></inline-formula> denominator (no reads for that ASC in that sample) to the mean across all other samples. These values were then (1) <inline-formula><mml:math id="inf245"><mml:mi>z</mml:mi></mml:math></inline-formula>-score normalized across samples and (2) quantile normalized to a normal across introns. QTL mapping was then performed using suez considering each intron as a ‘gene’.</p></sec><sec id="s4-13"><title>Modeling cardiac troponin level</title><p>We assessed the proportion of variance in cardiac troponin explained by gene expression response. Let <inline-formula><mml:math id="inf246"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> represent the troponin level measured in individual <inline-formula><mml:math id="inf247"><mml:mi>i</mml:mi></mml:math></inline-formula> at doxorubicin concentration <inline-formula><mml:math id="inf248"><mml:mi>c</mml:mi></mml:math></inline-formula>, normalized to have 0 mean and variance 1 across individuals at each concentration. Let <inline-formula><mml:math id="inf249"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> be the expression of gene <inline-formula><mml:math id="inf250"><mml:mi>g</mml:mi></mml:math></inline-formula> (in individual <inline-formula><mml:math id="inf251"><mml:mi>i</mml:mi></mml:math></inline-formula> at concentration <inline-formula><mml:math id="inf252"><mml:mi>c</mml:mi></mml:math></inline-formula>), <inline-formula><mml:math id="inf253"><mml:mi>z</mml:mi></mml:math></inline-formula>-score normalized across samples. We consider the linear model<disp-formula id="equ12"><label>(10)</label><mml:math id="m12"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>g</mml:mi></mml:munder></mml:mstyle><mml:mtext> </mml:mtext><mml:msub><mml:mi>β</mml:mi><mml:mi>g</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="inf254"><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ϵ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> is noise and the coefficients <inline-formula><mml:math id="inf255"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> are given a prior <inline-formula><mml:math id="inf256"><mml:mrow><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:mi>G</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> where <inline-formula><mml:math id="inf257"><mml:mrow><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mn>12</mml:mn><mml:mo>,</mml:mo><mml:mn>317</mml:mn></mml:mrow></mml:math></inline-formula> is the number of genes in the analysis. Integrating over <inline-formula><mml:math id="inf258"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> we have<disp-formula id="equ13"><label>(11)</label><mml:math id="m13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo>:</mml:mo></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mfrac><mml:mn>1</mml:mn><mml:mi>G</mml:mi></mml:mfrac><mml:munder><mml:mo>∑</mml:mo><mml:mi>g</mml:mi></mml:munder><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mo>:</mml:mo><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mo>:</mml:mo><mml:mi>g</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ϵ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mi>I</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>We optimize this model wrt <inline-formula><mml:math id="inf259"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>β</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="inf260"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mi>ϵ</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> to obtain an estimate <inline-formula><mml:math id="inf261"><mml:mrow><mml:mi>ρ</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ϵ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> of the percent variance of <inline-formula><mml:math id="inf262"><mml:mi>y</mml:mi></mml:math></inline-formula> explained by <inline-formula><mml:math id="inf263"><mml:mi>x</mml:mi></mml:math></inline-formula>. A Bayesian credible interval for <inline-formula><mml:math id="inf264"><mml:mi>ρ</mml:mi></mml:math></inline-formula> is obtained under this model using 8000 iterations of Hamiltonian Monte Carlo (with the first 4000 discarded as burnin) implemented using RStan (<xref ref-type="bibr" rid="bib8">Carpenter et al., 2016</xref>) (v2.16.2).</p><p>For the transcriptome-wide association study for cardiac troponin levels we use the R package glmnet (v2.0–13) to build elastic-net predictors of gene expression for each gene, using 10-fold cross-validation to choose <inline-formula><mml:math id="inf265"><mml:mi>λ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf266"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> which we found gave comparable performance to higher values. A single model was learnt per gene jointly across concentrations, including main effects for all SNPs within 100 kb of the gene TSS, main effects for doxorubicin dosage (encoded categorically) and interaction terms between each SNP and the dosage factor. The fitted values on the test-folds from the cross-validation are known as the ‘prevalidation’ response. To test which genes have a significant genetic component we tested (using analysis-of-variance) whether the observed expression was better predicted under a linear model including the prevalidation values and the dosage variable than by dosage alone. The prevalidated response for the 3840/12317 genes (1% FDR) genes that are predictable from genotype are then used to predict troponin level, normalized as for <xref ref-type="disp-formula" rid="equ12">Equation 10</xref>, using leave-out-one-cross-validated lasso regression.</p></sec><sec id="s4-14"><title>Code and data availability</title><p>All the custom analysis scripts used for this project are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/davidaknowles/dox">https://github.com/davidaknowles/dox</ext-link> (<xref ref-type="bibr" rid="bib26">Knowles and Blischak, 2017</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/dox">https://github.com/elifesciences-publications/dox</ext-link>). The suez response eQTL mapping R package is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/davidaknowles/suez">https://github.com/davidaknowles/suez</ext-link> (<xref ref-type="bibr" rid="bib28">Knowles, 2017</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/suez">https://github.com/elifesciences-publications/suez</ext-link>). The following data are available as Supplementary Data: (1) differential expression cluster assignments, (2) significant (5% FDR) eQTLs and sQTLs, (3) differential splicing results, (4) levels of cardiac troponin and the predicted transcriptomic response. In addition to the Supplementary Data included with this paper additional results are hosted at <ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/~dak33/dox/">http://web.stanford.edu/~dak33/dox/</ext-link> and Dryad (doi:10.5061/dryad.r5t8d04) including (1) gene-by-sample matrix of RNA-seq quantification (log counts per million), (2) LeafCutter intron excision quantification (3) <italic>p</italic>-values for all tested eQTLs, reQTLs, sQTLs, and rsQTLs, (4) RARG variant response and marginal trans-eQTLs, (5) RIN, RNA concentration and other technical covariates, (6) embryoid body imaging for all iPSC lines. The RNA-seq FASTQ files will be added to the dbGaP database (<xref ref-type="bibr" rid="bib55">Tryka et al., 2014</xref>) under dbGaP accession phs000185 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000185">https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000185</ext-link>). The genotype data files cannot be shared because releasing genotype data from a subset of individuals in the pedigree would enable the reconstruction of genotypes of other members of the pedigree, which would violate the original protocol approved by the research ethics board (<xref ref-type="bibr" rid="bib35">Livne et al., 2015</xref>). The summary statistics for the ACT GWAS were given to us by the authors of the studies (<xref ref-type="bibr" rid="bib47">Schneider et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Serie et al., 2017</xref>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The idea for the study was developed through conversations with Julian Solway (University of Chicago). We gratefully acknowledge Bryan Schneider for providing GWAS summary statistics. This work was supported by the Howard Hughes Medical Institute, and the US National Institutes of Health (NIH grants HL092206, HG008140, HG009431). CKB was supported by a NIH (<ext-link ext-link-type="uri" xlink:href="http://www.ncats.nih.gov/ctsa">http://www.ncats.nih.gov/ctsa</ext-link>) Clinical and Translational Science Award 5 TL1 TR 432–7 pre-doctoral fellowship.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Software, Formal analysis, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con6"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Human Subjects work was approved by the University of Chicago IRB (protocol 10-416-B). Written informed consent was obtained from all participants.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.33480.027</object-id><label>Supplementary file 1.</label><caption><title>Assignment of each gene’s response profile to differing doxorubicin concentrations into one of 6 clusters.</title></caption><media mime-subtype="plain" mimetype="text" xlink:href="elife-33480-supp1-v2.txt"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.33480.028</object-id><label>Supplementary file 2.</label><caption><title>HOMER2 pathway enrichment for each cluster from <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</title><p>Cluster: One of six clusters. TermID: Gene set ID. Term: gene set name. Odds_ratio: enrichment of this gene set in this cluster compared to background. p: <inline-formula><mml:math id="inf267"><mml:mi>p</mml:mi></mml:math></inline-formula>-value from hypergeometric test. p_adjust: Benjamini-Hochberg adjusted <inline-formula><mml:math id="inf268"><mml:mi>p</mml:mi></mml:math></inline-formula>-value. Overlap: number of genes shared by the gene set and the cluster. cluster_size: number of genes not in the cluster. Geneset_size: number of genes in the cluster. Total genes: total number of genes considered.</p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp2-v2.gz"/></supplementary-material><supplementary-material id="supp3"><object-id pub-id-type="doi">10.7554/eLife.33480.029</object-id><label>Supplementary file 3.</label><caption><title>HOMER2 promoter motif enrichment for each cluster from <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</title><p>cluster: One of six clusters. motif_info: full motif name including GEO source if applicable. motif: name of transcription factor. mphConsensus: consensus motif using IUPAC notation. odds_ratio: enrichment of motif in promoters of genes in this cluster compared to background. log_p: log <inline-formula><mml:math id="inf269"><mml:mi>p</mml:mi></mml:math></inline-formula>-value from hypergeometric test. p_adjust: Benjamini-Hochberg adjusted <inline-formula><mml:math id="inf270"><mml:mi>p</mml:mi></mml:math></inline-formula>-value. Overlap: number of genes in the cluster with this motif in their promoter. Background_overlap: number of genes not in the cluster with this motif in their promoter. cluster_size: number of genes not in the cluster. hbackground_size: number of genes not in the cluster.</p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp3-v2.gz"/></supplementary-material><supplementary-material id="supp4"><object-id pub-id-type="doi">10.7554/eLife.33480.030</object-id><label>Supplementary file 4.</label><caption><title>All significant (5% FDR) marginal effect eQTL.</title><p>gene: Ensembl gene ID. chr: Chromosome. pos: eSNP position. RSID: Rapid Stain Identification Series of the eSNP. p: <inline-formula><mml:math id="inf271"><mml:mi>p</mml:mi></mml:math></inline-formula> from suez Bonferroni corrected for the number of SNPs tested for the gene. q: Benjamini-Hochberg adjusted <inline-formula><mml:math id="inf272"><mml:mi>p</mml:mi></mml:math></inline-formula>-value.</p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp4-v2.gz"/></supplementary-material><supplementary-material id="supp5"><object-id pub-id-type="doi">10.7554/eLife.33480.031</object-id><label>Supplementary file 5.</label><caption><title>All significant (5% FDR) response eQTL using total expression only.</title><p>Columns are as for <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref></p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp5-v2.gz"/></supplementary-material><supplementary-material id="supp6"><object-id pub-id-type="doi">10.7554/eLife.33480.032</object-id><label>Supplementary file 6.</label><caption><title>All significant (5% FDR) response eQTL mapped using total and allele specific expression.</title><p>Columns are as for <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref></p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp6-v2.gz"/></supplementary-material><supplementary-material id="supp7"><object-id pub-id-type="doi">10.7554/eLife.33480.033</object-id><label>Supplementary file 7.</label><caption><title>LeafCutter splicing clusters and their association with doxorubicin concentration. cluster: Cluster ID.</title><p>p: <inline-formula><mml:math id="inf273"><mml:mi>p</mml:mi></mml:math></inline-formula>-value for Dirichlet-Multinomial GLM likelihood ratio test for differential splicing across doxorubicin concentrations. q: Benjamini-Hochberg adjusted <inline-formula><mml:math id="inf274"><mml:mi>p</mml:mi></mml:math></inline-formula>-value.</p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp7-v2.gz"/></supplementary-material><supplementary-material id="supp8"><object-id pub-id-type="doi">10.7554/eLife.33480.034</object-id><label>Supplementary file 8.</label><caption><title>LeafCutter estimates of Percent Spliced In (PSI) for each splice junction (intron) at each doxorubicin concentration.</title></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp8-v2.gz"/></supplementary-material><supplementary-material id="supp9"><object-id pub-id-type="doi">10.7554/eLife.33480.035</object-id><label>Supplementary file 9.</label><caption><title>Splicing QTL mapped using LeafCutter and suez.</title><p>Columns are as for <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> except that column one is the splice junction (intron) rather than the gene.</p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp9-v2.gz"/></supplementary-material><supplementary-material id="supp10"><object-id pub-id-type="doi">10.7554/eLife.33480.036</object-id><label>Supplementary file 10.</label><caption><title>Splicing response QTL mapped using LeafCutter and suez.</title><p>Columns are as for <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>.</p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp10-v2.gz"/></supplementary-material><supplementary-material id="supp11"><object-id pub-id-type="doi">10.7554/eLife.33480.037</object-id><label>Supplementary file 11.</label><caption><title>Cardiac troponin levels at different doxorubicin dosages.</title><p>cell_line: internal cell line ID and replicate number. dbgap: individual ID in dbGaP. dosage: doxorubicin concentration. troponin: cardiac troponin level.</p></caption><media mime-subtype="plain" mimetype="text" xlink:href="elife-33480-supp11-v2.txt"/></supplementary-material><supplementary-material id="supp12"><object-id pub-id-type="doi">10.7554/eLife.33480.038</object-id><label>Supplementary file 12.</label><caption><title>Optimal lasso model predicting normalized troponin level from gene expression.</title><p>Troponin level was normalized to be zero-mean and unit-variance across individuals at each concentration. gene: Ensembl gene id. hugo: HUGO approved gene symbol. beta: regression coefficient from lasso.</p></caption><media mime-subtype="plain" mimetype="text" xlink:href="elife-33480-supp12-v2.txt"/></supplementary-material><supplementary-material id="supp13"><object-id pub-id-type="doi">10.7554/eLife.33480.039</object-id><label>Supplementary file 13.</label><caption><title>Optimal lasso model predicting normalized troponin level from the component of gene expression predictable from genotype.</title><p>Troponin level was normalized to be zero-mean and unit-variance across individuals at each concentration. gene: Ensembl gene id. hugo: HUGO approved gene symbol. beta: regression coefficient from lasso.</p></caption><media mime-subtype="plain" mimetype="text" xlink:href="elife-33480-supp13-v2.txt"/></supplementary-material><supplementary-material id="supp14"><object-id pub-id-type="doi">10.7554/eLife.33480.040</object-id><label>Supplementary file 14.</label><caption><title>Genes significantly differentially expressed with respect to troponin level at each doxorubicin concentration.</title><p>conc: doxorubicin concentration. gene: Ensembl gene id. rho: Spearman correlation between gene expression and troponin level. p: Spearman correlation <inline-formula><mml:math id="inf275"><mml:mi>p</mml:mi></mml:math></inline-formula>-value. p_adjust: Benjamini-Hochberg adjusted <inline-formula><mml:math id="inf276"><mml:mi>p</mml:mi></mml:math></inline-formula>-value.</p></caption><media mime-subtype="x-gzip" mimetype="application" xlink:href="elife-33480-supp14-v2.gz"/></supplementary-material><supplementary-material id="supp15"><object-id pub-id-type="doi">10.7554/eLife.33480.041</object-id><label>Supplementary file 15.</label><caption><title>Optimal lasso model predicting ACT risk from gene expression using previously published data (<xref ref-type="bibr" rid="bib5">Burridge et al., 2016</xref>).</title><p>gene: Ensembl gene id. beta: regression coefficient from lasso.</p></caption><media mime-subtype="plain" mimetype="text" xlink:href="elife-33480-supp15-v2.txt"/></supplementary-material><supplementary-material id="supp16"><object-id pub-id-type="doi">10.7554/eLife.33480.042</object-id><label>Supplementary file 16.</label><caption><title>Colocalization analysis of response-eQTL and ACT GWAS.</title><p>gene: Ensembl gene id. snps: number of SNPs tested. PP.H0.abf: posterior probability of no association. PP.H1.abf: posterior probability of GWAS association only. PP.H2.abf posterior probability of reQTL only. PP.H3.abf: posterior probability of GWAS variant and reQTL being independent. PP.H4.abf: posterior probability of GWAS and reQTL colocalizing to the same variant.fa</p></caption><media mime-subtype="plain" mimetype="text" xlink:href="elife-33480-supp16-v2.txt"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.33480.043</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-33480-transrepform-v2.pdf"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All the custom analysis scripts used for this project are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/davidaknowles/dox">https://github.com/davidaknowles/dox</ext-link> (Knowles and Blischak, 2017). The suez response eQTL mapping R package is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/davidaknowles/suez">https://github.com/davidaknowles/suez</ext-link> (Knowles, 2017). The following data are available as Supplementary Data: 1) differential expression cluster assignments, 2) significant (5% FDR) eQTLs and sQTLs, 3) differential splicing results, 4) levels of cardiac troponin and the predicted transcriptomic response. In addition to the Supplementary Data included with this paper, further results are hosted at Dryad (doi:10.5061/dryad.r5t8d04) including 1) gene-by-sample matrix of RNA-seq quantification (log counts per million), 2) LeafCutter intron excision quantification 3) p-values for all tested eQTLs, reQTLs, sQTLs, and rsQTLs, 4) RARG variant response and marginal trans-eQTLs, 5) RIN, RNA concentration and other technical covariates, 6) embryoid body imaging for all iPSC lines. The RNA-seq FASTQ files will be added to the dbGaP database (Tryka et al., 2014) under dbGaP accession phs000185 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000185">https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000185</ext-link>). The genotype data files cannot be shared because releasing genotype data from a subset of individuals in the pedigree would enable the reconstruction of genotypes of other members of the pedigree, which would violate the original protocol approved by the research ethics board (Livne et al., 2015). The summary statistics for the ACT GWAS were given to us by the authors of the study (Schneider et al., 2016; Serie et al. 2017).</p><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataset1" source-id="http://dx.doi.org/10.5061/dryad.r5t8d04" source-id-type="uri"><collab collab-type="author">Knowles DA</collab><collab collab-type="author">Courtney K Burrows</collab><collab collab-type="author">John D Blischak</collab><collab collab-type="author">Carole Ober</collab><collab collab-type="author">Jonathan K Pritchard</collab><collab collab-type="author">Yoav Gilad</collab><year>2018</year><source>Expression and splicing quantification, eQTLs and sQTLs</source><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5061/dryad.r5t8d04">http://dx.doi.org/10.5061/dryad.r5t8d04</ext-link><comment>Available at Dryad Digital Repository under a CC0 Public Domain Dedication</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset2" source-id="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000185" source-id-type="uri"><collab collab-type="author">Courtney K Burrows</collab><collab collab-type="author">Knowles DA</collab><collab collab-type="author">John D Blischak</collab><collab collab-type="author">Kristen M Patterson</collab><collab collab-type="author">Carole Ober</collab><collab collab-type="author">Jonathan K Pritchard</collab><collab collab-type="author">Yoav Gilad</collab><year>2018</year><source>Genetic Studies in the Hutterites</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000185">https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000185</ext-link><comment>Available at dbGaP via dbGaP Authorized Access (accession no. phs000185.v5.p1)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Alasoo</surname> <given-names>K</given-names></name><name><surname>Rodrigues</surname> <given-names>J</given-names></name><name><surname>Mukhopadhyay</surname> <given-names>S</given-names></name><name><surname>Knights</surname> <given-names>AJ</given-names></name><name><surname>Mann</surname> <given-names>AL</given-names></name><name><surname>Kundu</surname> <given-names>K</given-names></name><name><surname>Hale</surname> <given-names>C</given-names></name><name><surname>Dougan</surname> <given-names>G</given-names></name><name><surname>Gaffney</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Shared genetic effects on chromatin and gene expression reveal widespread enhancer priming in immune response</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/102392</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aminkeng</surname> <given-names>F</given-names></name><name><surname>Bhavsar</surname> <given-names>AP</given-names></name><name><surname>Visscher</surname> <given-names>H</given-names></name><name><surname>Rassekh</surname> <given-names>SR</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name><name><surname>Brunham</surname> <given-names>LR</given-names></name><name><surname>Caron</surname> <given-names>HN</given-names></name><name><surname>van Dalen</surname> <given-names>EC</given-names></name><name><surname>Kremer</surname> <given-names>LC</given-names></name><name><surname>van der Pal</surname> <given-names>HJ</given-names></name><name><surname>Amstutz</surname> <given-names>U</given-names></name><name><surname>Rieder</surname> <given-names>MJ</given-names></name><name><surname>Bernstein</surname> <given-names>D</given-names></name><name><surname>Carleton</surname> <given-names>BC</given-names></name><name><surname>Hayden</surname> <given-names>MR</given-names></name><name><surname>Ross</surname> <given-names>CJ</given-names></name><name><surname>Dalen</surname> <given-names>ECvan</given-names></name><name><surname>Pal</surname> <given-names>HJvander</given-names></name><name><surname>Hayden</surname> <given-names>MR</given-names></name><name><surname>Carleton</surname> <given-names>BC</given-names></name><name><surname>Ross</surname> <given-names>CJD</given-names></name><name><surname>MacLeod</surname> <given-names>S</given-names></name><name><surname>Smith</surname> <given-names>A</given-names></name><name><surname>Hildebrand</surname> <given-names>C</given-names></name><name><surname>Ghannadan</surname> <given-names>R</given-names></name><name><surname>Rassekh</surname> <given-names>SR</given-names></name><name><surname>Visscher</surname> <given-names>H</given-names></name><name><surname>Aminkeng</surname> <given-names>F</given-names></name><name><surname>Miao</surname> <given-names>F</given-names></name><name><surname>Higginson</surname> <given-names>M</given-names></name><name><surname>Massah</surname> <given-names>N</given-names></name><name><surname>Borrie</surname> <given-names>A</given-names></name><name><surname>Amstutz</surname> <given-names>U</given-names></name><name><surname>Hughes</surname> <given-names>S</given-names></name><name><surname>Shaw</surname> <given-names>K</given-names></name><name><surname>Dhoot</surname> <given-names>S</given-names></name><name><surname>Bhavsar</surname> <given-names>AP</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name><name><surname>Kowalec</surname> <given-names>K</given-names></name><name><surname>Stortz</surname> <given-names>J</given-names></name><name><surname>Bendyshe-Walton</surname> <given-names>T</given-names></name><name><surname>Waltrip</surname> <given-names>D</given-names></name><name><surname>Bader</surname> <given-names>R</given-names></name><name><surname>Nijssen-Jordan</surname> <given-names>C</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Verbeek</surname> <given-names>L</given-names></name><name><surname>Kaczowka</surname> <given-names>R</given-names></name><name><surname>Stevenson</surname> <given-names>P</given-names></name><name><surname>Zhuwaki</surname> <given-names>C</given-names></name><name><surname>Grundy</surname> <given-names>P</given-names></name><name><surname>Stobart</surname> <given-names>K</given-names></name><name><surname>Wilson</surname> <given-names>B</given-names></name><name><surname>Desai</surname> <given-names>S</given-names></name><name><surname>Spavor</surname> <given-names>M</given-names></name><name><surname>Churcher</surname> <given-names>L</given-names></name><name><surname>Chow</surname> <given-names>T</given-names></name><name><surname>Hall</surname> <given-names>K</given-names></name><name><surname>Honcharik</surname> <given-names>N</given-names></name><name><surname>Israels</surname> <given-names>S</given-names></name><name><surname>Chan</surname> <given-names>S</given-names></name><name><surname>Garnham</surname> <given-names>B</given-names></name><name><surname>Staub</surname> <given-names>M</given-names></name><collab>Canadian Pharmacogenomics Network for Drug Safety Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1079</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1038/ng.3374</pub-id><pub-id pub-id-type="pmid">26237429</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angrist</surname> <given-names>JD</given-names></name><name><surname>Imbens</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Two-Stage least squares estimation of average causal effects in models with variable treatment intensity</article-title><source>Journal of the American Statistical Association</source><volume>90</volume><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1080/01621459.1995.10476535</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banovich</surname> <given-names>NE</given-names></name><name><surname>Li</surname> <given-names>YI</given-names></name><name><surname>Raj</surname> <given-names>A</given-names></name><name><surname>Ward</surname> <given-names>MC</given-names></name><name><surname>Greenside</surname> <given-names>P</given-names></name><name><surname>Calderon</surname> <given-names>D</given-names></name><name><surname>Tung</surname> <given-names>PY</given-names></name><name><surname>Burnett</surname> <given-names>JE</given-names></name><name><surname>Myrthil</surname> <given-names>M</given-names></name><name><surname>Thomas</surname> <given-names>SM</given-names></name><name><surname>Burrows</surname> <given-names>CK</given-names></name><name><surname>Romero</surname> <given-names>IG</given-names></name><name><surname>Pavlovic</surname> <given-names>BJ</given-names></name><name><surname>Kundaje</surname> <given-names>A</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impact of regulatory variation across human iPSCs and differentiated cells</article-title><source>Genome research</source><volume>28</volume><ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/early/2016/12/05/091660">https://www.biorxiv.org/content/early/2016/12/05/091660</ext-link><pub-id pub-id-type="doi">10.1101/gr.224436.117</pub-id><pub-id pub-id-type="pmid">29208628</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burridge</surname> <given-names>PW</given-names></name><name><surname>Li</surname> <given-names>YF</given-names></name><name><surname>Matsa</surname> <given-names>E</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Ong</surname> <given-names>S-G</given-names></name><name><surname>Sharma</surname> <given-names>A</given-names></name><name><surname>Holmström</surname> <given-names>A</given-names></name><name><surname>Chang</surname> <given-names>AC</given-names></name><name><surname>Coronado</surname> <given-names>MJ</given-names></name><name><surname>Ebert</surname> <given-names>AD</given-names></name><name><surname>Knowles</surname> <given-names>JW</given-names></name><name><surname>Telli</surname> <given-names>ML</given-names></name><name><surname>Witteles</surname> <given-names>RM</given-names></name><name><surname>Blau</surname> <given-names>HM</given-names></name><name><surname>Bernstein</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Russ B Altman, and Joseph C Wu. human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast Cancer patients to doxorubicin-induced cardiotoxicity.-supple</article-title><source>Nature Medicine</source><volume>220</volume><fpage>547</fpage><lpage>556</lpage></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burridge</surname> <given-names>PW</given-names></name><name><surname>Matsa</surname> <given-names>E</given-names></name><name><surname>Shukla</surname> <given-names>P</given-names></name><name><surname>Lin</surname> <given-names>ZC</given-names></name><name><surname>Churko</surname> <given-names>JM</given-names></name><name><surname>Ebert</surname> <given-names>AD</given-names></name><name><surname>Lan</surname> <given-names>F</given-names></name><name><surname>Diecke</surname> <given-names>S</given-names></name><name><surname>Huber</surname> <given-names>B</given-names></name><name><surname>Mordwinkin</surname> <given-names>NM</given-names></name><name><surname>Plews</surname> <given-names>JR</given-names></name><name><surname>Abilez</surname> <given-names>OJ</given-names></name><name><surname>Cui</surname> <given-names>B</given-names></name><name><surname>Gold</surname> <given-names>JD</given-names></name><name><surname>Wu</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chemically defined generation of human cardiomyocytes</article-title><source>Nature Methods</source><volume>11</volume><fpage>855</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2999</pub-id><pub-id pub-id-type="pmid">24930130</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrows</surname> <given-names>CK</given-names></name><name><surname>Banovich</surname> <given-names>NE</given-names></name><name><surname>Pavlovic</surname> <given-names>BJ</given-names></name><name><surname>Patterson</surname> <given-names>K</given-names></name><name><surname>Gallego Romero</surname> <given-names>I</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetic variation, not cell type of origin, underlies the majority of identifiable regulatory differences in iPSCs</article-title><source>PLOS Genetics</source><volume>12</volume><fpage>e1005793</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1005793</pub-id><pub-id pub-id-type="pmid">26812582</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname> <given-names>B</given-names></name><name><surname>Gelman</surname> <given-names>A</given-names></name><name><surname>Hoffman</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>D</given-names></name><name><surname>Goodrich</surname> <given-names>B</given-names></name><name><surname>Betancourt</surname> <given-names>M</given-names></name><name><surname>Brubaker</surname> <given-names>MA</given-names></name><name><surname>Guo</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Riddell</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stan: a probabilistic programming language</article-title><source>Journal of Statistical Software</source><volume>20</volume><fpage>1</fpage><lpage>37</lpage></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascales</surname> <given-names>A</given-names></name><name><surname>Pastor-Quirante</surname> <given-names>F</given-names></name><name><surname>Sánchez-Vega</surname> <given-names>B</given-names></name><name><surname>Luengo-Gil</surname> <given-names>G</given-names></name><name><surname>Corral</surname> <given-names>J</given-names></name><name><surname>Ortuño-Pacheco</surname> <given-names>G</given-names></name><name><surname>Vicente</surname> <given-names>V</given-names></name><name><surname>de la Peña</surname> <given-names>FA</given-names></name><name><surname>Peña</surname> <given-names>FAdela</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms</article-title><source>The Oncologist</source><volume>18</volume><fpage>446</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2012-0239</pub-id><pub-id pub-id-type="pmid">23576480</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusanovich</surname> <given-names>DA</given-names></name><name><surname>Billstrand</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Chavarria</surname> <given-names>C</given-names></name><name><surname>De Leon</surname> <given-names>S</given-names></name><name><surname>Michelini</surname> <given-names>K</given-names></name><name><surname>Pai</surname> <given-names>AA</given-names></name><name><surname>Ober</surname> <given-names>C</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>2111</fpage><lpage>2123</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds021</pub-id><pub-id pub-id-type="pmid">22286170</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusanovich</surname> <given-names>DA</given-names></name><name><surname>Caliskan</surname> <given-names>M</given-names></name><name><surname>Billstrand</surname> <given-names>C</given-names></name><name><surname>Michelini</surname> <given-names>K</given-names></name><name><surname>Chavarria</surname> <given-names>C</given-names></name><name><surname>De Leon</surname> <given-names>S</given-names></name><name><surname>Mitrano</surname> <given-names>A</given-names></name><name><surname>Lewellyn</surname> <given-names>N</given-names></name><name><surname>Elias</surname> <given-names>JA</given-names></name><name><surname>Chupp</surname> <given-names>GL</given-names></name><name><surname>Lang</surname> <given-names>RM</given-names></name><name><surname>Shah</surname> <given-names>SJ</given-names></name><name><surname>Decara</surname> <given-names>JM</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name><name><surname>Ober</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Integrated analyses of gene expression and genetic association studies in a founder population</article-title><source>Human Molecular Genetics</source><volume>25</volume><fpage>2104</fpage><lpage>2112</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw061</pub-id><pub-id pub-id-type="pmid">26931462</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Disher</surname> <given-names>K</given-names></name><name><surname>Skandalis</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Evidence of the modulation of mRNA splicing fidelity in humans by oxidative stress and p53</article-title><source>Genome</source><volume>50</volume><fpage>946</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1139/G07-074</pub-id><pub-id pub-id-type="pmid">18059557</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewels</surname> <given-names>P</given-names></name><name><surname>Magnusson</surname> <given-names>M</given-names></name><name><surname>Lundin</surname> <given-names>S</given-names></name><name><surname>Käller</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MultiQC: summarize analysis results for multiple tools and samples in a single report</article-title><source>Bioinformatics</source><volume>32</volume><fpage>3047</fpage><lpage>3048</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw354</pub-id><pub-id pub-id-type="pmid">27312411</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhad</surname> <given-names>H</given-names></name><name><surname>Staziaki</surname> <given-names>PV</given-names></name><name><surname>Addison</surname> <given-names>D</given-names></name><name><surname>Coelho-Filho</surname> <given-names>OR</given-names></name><name><surname>Shah</surname> <given-names>RV</given-names></name><name><surname>Mitchell</surname> <given-names>RN</given-names></name><name><surname>Szilveszter</surname> <given-names>B</given-names></name><name><surname>Abbasi</surname> <given-names>SA</given-names></name><name><surname>Kwong</surname> <given-names>RY</given-names></name><name><surname>Scherrer-Crosbie</surname> <given-names>M</given-names></name><name><surname>Hoffmann</surname> <given-names>U</given-names></name><name><surname>Jerosch-Herold</surname> <given-names>M</given-names></name><name><surname>Neilan</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging</article-title><source>Circulation: Cardiovascular Imaging</source><volume>9</volume><elocation-id>e003584</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.115.003584</pub-id><pub-id pub-id-type="pmid">27923796</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusi</surname> <given-names>N</given-names></name><name><surname>Stegle</surname> <given-names>O</given-names></name><name><surname>Lawrence</surname> <given-names>ND</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Joint modelling of confounding factors and prominent genetic regulators provides increased accuracy in genetical genomics studies</article-title><source>PLoS Computational Biology</source><volume>8</volume><fpage>e1002330</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002330</pub-id><pub-id pub-id-type="pmid">22241974</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallego Romero</surname> <given-names>I</given-names></name><name><surname>Pavlovic</surname> <given-names>BJ</given-names></name><name><surname>Hernando-Herraez</surname> <given-names>I</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Ward</surname> <given-names>MC</given-names></name><name><surname>Banovich</surname> <given-names>NE</given-names></name><name><surname>Kagan</surname> <given-names>CL</given-names></name><name><surname>Burnett</surname> <given-names>JE</given-names></name><name><surname>Huang</surname> <given-names>CH</given-names></name><name><surname>Mitrano</surname> <given-names>A</given-names></name><name><surname>Chavarria</surname> <given-names>CI</given-names></name><name><surname>Friedrich Ben-Nun</surname> <given-names>I</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Sabatini</surname> <given-names>K</given-names></name><name><surname>Leonardo</surname> <given-names>TR</given-names></name><name><surname>Parast</surname> <given-names>M</given-names></name><name><surname>Marques-Bonet</surname> <given-names>T</given-names></name><name><surname>Laurent</surname> <given-names>LC</given-names></name><name><surname>Loring</surname> <given-names>JF</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A panel of induced pluripotent stem cells from chimpanzees: a resource for comparative functional genomics</article-title><source>eLife</source><volume>4</volume><elocation-id>e07103</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.07103</pub-id><pub-id pub-id-type="pmid">26102527</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamazon</surname> <given-names>ER</given-names></name><name><surname>Wheeler</surname> <given-names>HE</given-names></name><name><surname>Shah</surname> <given-names>KP</given-names></name><name><surname>Mozaffari</surname> <given-names>SV</given-names></name><name><surname>Aquino-Michaels</surname> <given-names>K</given-names></name><name><surname>Carroll</surname> <given-names>RJ</given-names></name><name><surname>Eyler</surname> <given-names>AE</given-names></name><name><surname>Denny</surname> <given-names>JC</given-names></name><name><surname>Nicolae</surname> <given-names>DL</given-names></name><name><surname>Cox</surname> <given-names>NJ</given-names></name><name><surname>Im</surname> <given-names>HK</given-names></name><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>A gene-based association method for mapping traits using reference transcriptome data</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1091</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1038/ng.3367</pub-id><pub-id pub-id-type="pmid">26258848</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giambartolomei</surname> <given-names>C</given-names></name><name><surname>Vukcevic</surname> <given-names>D</given-names></name><name><surname>Schadt</surname> <given-names>EE</given-names></name><name><surname>Franke</surname> <given-names>L</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Wallace</surname> <given-names>C</given-names></name><name><surname>Plagnol</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bayesian test for colocalisation between pairs of genetic association studies using summary statistics</article-title><source>PLoS Genetics</source><volume>10</volume><elocation-id>e1004383</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmid">24830394</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graessmann</surname> <given-names>M</given-names></name><name><surname>Berg</surname> <given-names>B</given-names></name><name><surname>Fuchs</surname> <given-names>B</given-names></name><name><surname>Klein</surname> <given-names>A</given-names></name><name><surname>Graessmann</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3</article-title><source>Oncogene</source><volume>26</volume><elocation-id>2840</elocation-id><lpage>2850</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210096</pub-id><pub-id pub-id-type="pmid">17160024</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastie</surname> <given-names>T</given-names></name><name><surname>Stuetzle</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Principal curves</article-title><source>Journal of the American Statistical Association</source><volume>84</volume><fpage>502</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1080/01621459.1989.10478797</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heck</surname> <given-names>SL</given-names></name><name><surname>Gulati</surname> <given-names>G</given-names></name><name><surname>Hoffmann</surname> <given-names>P</given-names></name><name><surname>von Knobelsdorff-Brenkenhoff</surname> <given-names>F</given-names></name><name><surname>Storås</surname> <given-names>TH</given-names></name><name><surname>Ree</surname> <given-names>AH</given-names></name><name><surname>Gravdehaug</surname> <given-names>B</given-names></name><name><surname>Røsjø</surname> <given-names>H</given-names></name><name><surname>Steine</surname> <given-names>K</given-names></name><name><surname>Geisler</surname> <given-names>J</given-names></name><name><surname>Schulz-Menger</surname> <given-names>J</given-names></name><name><surname>Omland</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial</article-title><source>European heart journal cardiovascular Imaging</source><pub-id pub-id-type="doi">10.1093/ehjci/jex159</pub-id><pub-id pub-id-type="pmid">29106497</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname> <given-names>S</given-names></name><name><surname>Benner</surname> <given-names>C</given-names></name><name><surname>Spann</surname> <given-names>N</given-names></name><name><surname>Bertolino</surname> <given-names>E</given-names></name><name><surname>Lin</surname> <given-names>YC</given-names></name><name><surname>Laslo</surname> <given-names>P</given-names></name><name><surname>Cheng</surname> <given-names>JX</given-names></name><name><surname>Murre</surname> <given-names>C</given-names></name><name><surname>Singh</surname> <given-names>H</given-names></name><name><surname>Glass</surname> <given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities</article-title><source>Molecular Cell</source><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname> <given-names>G</given-names></name><name><surname>Flickinger</surname> <given-names>M</given-names></name><name><surname>Hetrick</surname> <given-names>KN</given-names></name><name><surname>Romm</surname> <given-names>JM</given-names></name><name><surname>Doheny</surname> <given-names>KF</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Kang</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data</article-title><source>The American Journal of Human Genetics</source><volume>91</volume><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2012.09.004</pub-id><pub-id pub-id-type="pmid">23103226</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilpinen</surname> <given-names>H</given-names></name><name><surname>Goncalves</surname> <given-names>A</given-names></name><name><surname>Leha</surname> <given-names>A</given-names></name><name><surname>Afzal</surname> <given-names>V</given-names></name><name><surname>Alasoo</surname> <given-names>K</given-names></name><name><surname>Ashford</surname> <given-names>S</given-names></name><name><surname>Bala</surname> <given-names>S</given-names></name><name><surname>Bensaddek</surname> <given-names>D</given-names></name><name><surname>Casale</surname> <given-names>FP</given-names></name><name><surname>Culley</surname> <given-names>OJ</given-names></name><name><surname>Danecek</surname> <given-names>P</given-names></name><name><surname>Faulconbridge</surname> <given-names>A</given-names></name><name><surname>Harrison</surname> <given-names>PW</given-names></name><name><surname>Kathuria</surname> <given-names>A</given-names></name><name><surname>McCarthy</surname> <given-names>D</given-names></name><name><surname>McCarthy</surname> <given-names>SA</given-names></name><name><surname>Meleckyte</surname> <given-names>R</given-names></name><name><surname>Memari</surname> <given-names>Y</given-names></name><name><surname>Moens</surname> <given-names>N</given-names></name><name><surname>Soares</surname> <given-names>F</given-names></name><name><surname>Mann</surname> <given-names>A</given-names></name><name><surname>Streeter</surname> <given-names>I</given-names></name><name><surname>Agu</surname> <given-names>CA</given-names></name><name><surname>Alderton</surname> <given-names>A</given-names></name><name><surname>Nelson</surname> <given-names>R</given-names></name><name><surname>Harper</surname> <given-names>S</given-names></name><name><surname>Patel</surname> <given-names>M</given-names></name><name><surname>White</surname> <given-names>A</given-names></name><name><surname>Patel</surname> <given-names>SR</given-names></name><name><surname>Clarke</surname> <given-names>L</given-names></name><name><surname>Halai</surname> <given-names>R</given-names></name><name><surname>Kirton</surname> <given-names>CM</given-names></name><name><surname>Kolb-Kokocinski</surname> <given-names>A</given-names></name><name><surname>Beales</surname> <given-names>P</given-names></name><name><surname>Birney</surname> <given-names>E</given-names></name><name><surname>Danovi</surname> <given-names>D</given-names></name><name><surname>Lamond</surname> <given-names>AI</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name><name><surname>Vallier</surname> <given-names>L</given-names></name><name><surname>Watt</surname> <given-names>FM</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name><name><surname>Stegle</surname> <given-names>O</given-names></name><name><surname>Gaffney</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Common genetic variation drives molecular heterogeneity in human iPSCs</article-title><source>Nature</source><volume>546</volume><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature22403</pub-id><pub-id pub-id-type="pmid">28489815</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Knowles</surname> <given-names>DA</given-names></name><name><surname>Blischak</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Analysis scripts for doxorubicin response in derived cardiomyocytes</data-title><version designator="c17b449">c17b449</version><publisher-name>Github</publisher-name><ext-link ext-link-type="uri" xlink:href="https://github.com/davidaknowles/dox/">https://github.com/davidaknowles/dox/</ext-link></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname> <given-names>DA</given-names></name><name><surname>Davis</surname> <given-names>JR</given-names></name><name><surname>Edgington</surname> <given-names>H</given-names></name><name><surname>Raj</surname> <given-names>A</given-names></name><name><surname>Favé</surname> <given-names>MJ</given-names></name><name><surname>Zhu</surname> <given-names>X</given-names></name><name><surname>Potash</surname> <given-names>JB</given-names></name><name><surname>Weissman</surname> <given-names>MM</given-names></name><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Levinson</surname> <given-names>DF</given-names></name><name><surname>Awadalla</surname> <given-names>P</given-names></name><name><surname>Mostafavi</surname> <given-names>S</given-names></name><name><surname>Montgomery</surname> <given-names>SB</given-names></name><name><surname>Battle</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Allele-specific expression reveals interactions between genetic variation and environment</article-title><source>Nature Methods</source><volume>14</volume><fpage>699</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4298</pub-id><pub-id pub-id-type="pmid">28530654</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Knowles</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>R package for mapping response-expression qtls</data-title><source>Github</source><version designator="29046f6">29046f6</version><ext-link ext-link-type="uri" xlink:href="https://github.com/davidaknowles/suez/">https://github.com/davidaknowles/suez/</ext-link></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumasaka</surname> <given-names>N</given-names></name><name><surname>Knights</surname> <given-names>AJ</given-names></name><name><surname>Gaffney</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fine-mapping cellular QTLs with RASQUAL and ATAC-seq</article-title><source>Nature Genetics</source><volume>48</volume><elocation-id>206</elocation-id><lpage>213</lpage><pub-id pub-id-type="doi">10.1038/ng.3467</pub-id><pub-id pub-id-type="pmid">26656845</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Handsaker</surname> <given-names>B</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Ruan</surname> <given-names>J</given-names></name><name><surname>Homer</surname> <given-names>N</given-names></name><name><surname>Marth</surname> <given-names>G</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The Sequence Alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>YI</given-names></name><name><surname>Knowles</surname> <given-names>DA</given-names></name><name><surname>Humphrey</surname> <given-names>J</given-names></name><name><surname>Barbeira</surname> <given-names>AN</given-names></name><name><surname>Dickinson</surname> <given-names>SP</given-names></name><name><surname>Im</surname> <given-names>HK</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>LeafCutter: annotation-free quantification of RNA splicing</article-title><source>Biorxiv</source><pub-id pub-id-type="doi">10.1101/044107</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>YI</given-names></name><name><surname>van de Geijn</surname> <given-names>B</given-names></name><name><surname>Raj</surname> <given-names>A</given-names></name><name><surname>Knowles</surname> <given-names>DA</given-names></name><name><surname>Petti</surname> <given-names>AA</given-names></name><name><surname>Golan</surname> <given-names>D</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNA splicing is a primary link between genetic variation and disease</article-title><source>Science</source><volume>352</volume><fpage>600</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1126/science.aad9417</pub-id><pub-id pub-id-type="pmid">27126046</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Azarin</surname> <given-names>SM</given-names></name><name><surname>Zhu</surname> <given-names>K</given-names></name><name><surname>Hazeltine</surname> <given-names>LB</given-names></name><name><surname>Bao</surname> <given-names>X</given-names></name><name><surname>Hsiao</surname> <given-names>C</given-names></name><name><surname>Kamp</surname> <given-names>TJ</given-names></name><name><surname>Palecek</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating wnt/β-catenin signaling under fully defined conditions</article-title><source>Nature Protocols</source><volume>8</volume><fpage>162</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.150</pub-id><pub-id pub-id-type="pmid">23257984</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livne</surname> <given-names>OE</given-names></name><name><surname>Han</surname> <given-names>L</given-names></name><name><surname>Alkorta-Aranburu</surname> <given-names>G</given-names></name><name><surname>Wentworth-Sheilds</surname> <given-names>W</given-names></name><name><surname>Abney</surname> <given-names>M</given-names></name><name><surname>Ober</surname> <given-names>C</given-names></name><name><surname>Nicolae</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PRIMAL: fast and accurate pedigree-based imputation from sequence data in a founder population</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004139</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004139</pub-id><pub-id pub-id-type="pmid">25735005</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ZNF143 transcription factor mediates cell survival through upregulation of the GPX1 activity in the mitochondrial respiratory dysfunction</article-title><source>Cell Death &amp; Disease</source><volume>3</volume><elocation-id>e422</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2012.156</pub-id><pub-id pub-id-type="pmid">23152058</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacEachern</surname> <given-names>SN</given-names></name><name><surname>Müller</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Estimating mixture of dirichlet process models</article-title><source>Journal of Computational and Graphical Statistics</source><volume>70</volume><fpage>223</fpage><lpage>238</lpage></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott-Roe</surname> <given-names>C</given-names></name><name><surname>Leleu</surname> <given-names>M</given-names></name><name><surname>Rowe</surname> <given-names>GC</given-names></name><name><surname>Palygin</surname> <given-names>O</given-names></name><name><surname>Bukowy</surname> <given-names>JD</given-names></name><name><surname>Kuo</surname> <given-names>J</given-names></name><name><surname>Rech</surname> <given-names>M</given-names></name><name><surname>Hermans-Beijnsberger</surname> <given-names>S</given-names></name><name><surname>Schaefer</surname> <given-names>S</given-names></name><name><surname>Adami</surname> <given-names>E</given-names></name><name><surname>Creemers</surname> <given-names>EE</given-names></name><name><surname>Heinig</surname> <given-names>M</given-names></name><name><surname>Schroen</surname> <given-names>B</given-names></name><name><surname>Arany</surname> <given-names>Z</given-names></name><name><surname>Petretto</surname> <given-names>E</given-names></name><name><surname>Geurts</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptome-wide co-expression analysis identifies LRRC2 as a novel mediator of mitochondrial and cardiac function</article-title><source>PLoS One</source><volume>12</volume><elocation-id>e0170458</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0170458</pub-id><pub-id pub-id-type="pmid">28158196</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melé</surname> <given-names>M</given-names></name><name><surname>Ferreira</surname> <given-names>PG</given-names></name><name><surname>Reverter</surname> <given-names>F</given-names></name><name><surname>DeLuca</surname> <given-names>DS</given-names></name><name><surname>Monlong</surname> <given-names>J</given-names></name><name><surname>Sammeth</surname> <given-names>M</given-names></name><name><surname>Young</surname> <given-names>TR</given-names></name><name><surname>Goldmann</surname> <given-names>JM</given-names></name><name><surname>Pervouchine</surname> <given-names>DD</given-names></name><name><surname>Sullivan</surname> <given-names>TJ</given-names></name><name><surname>Johnson</surname> <given-names>R</given-names></name><name><surname>Segrè</surname> <given-names>AV</given-names></name><name><surname>Djebali</surname> <given-names>S</given-names></name><name><surname>Niarchou</surname> <given-names>A</given-names></name><name><surname>Wright</surname> <given-names>FA</given-names></name><name><surname>Lappalainen</surname> <given-names>T</given-names></name><name><surname>Calvo</surname> <given-names>M</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Dermitzakis</surname> <given-names>ET</given-names></name><name><surname>Ardlie</surname> <given-names>KG</given-names></name><name><surname>Guigó</surname> <given-names>R</given-names></name><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Human genomics. The human transcriptome across tissues and individuals</article-title><source>Science</source><volume>348</volume><fpage>660</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1126/science.aaa0355</pub-id><pub-id pub-id-type="pmid">25954002</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname> <given-names>FJ</given-names></name><name><surname>Schuldt</surname> <given-names>BM</given-names></name><name><surname>Williams</surname> <given-names>R</given-names></name><name><surname>Mason</surname> <given-names>D</given-names></name><name><surname>Altun</surname> <given-names>G</given-names></name><name><surname>Papapetrou</surname> <given-names>EP</given-names></name><name><surname>Danner</surname> <given-names>S</given-names></name><name><surname>Goldmann</surname> <given-names>JE</given-names></name><name><surname>Herbst</surname> <given-names>A</given-names></name><name><surname>Schmidt</surname> <given-names>NO</given-names></name><name><surname>Aldenhoff</surname> <given-names>JB</given-names></name><name><surname>Laurent</surname> <given-names>LC</given-names></name><name><surname>Loring</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A bioinformatic assay for pluripotency in human cells</article-title><source>Nature Methods</source><volume>8</volume><fpage>315</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1580</pub-id><pub-id pub-id-type="pmid">21378979</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>DL</given-names></name><name><surname>Hoffjan</surname> <given-names>S</given-names></name><name><surname>Bourgain</surname> <given-names>C</given-names></name><name><surname>Abney</surname> <given-names>M</given-names></name><name><surname>Nicolae</surname> <given-names>RI</given-names></name><name><surname>Profits</surname> <given-names>ET</given-names></name><name><surname>Grow</surname> <given-names>MA</given-names></name><name><surname>Walker</surname> <given-names>K</given-names></name><name><surname>Steiner</surname> <given-names>L</given-names></name><name><surname>Parry</surname> <given-names>R</given-names></name><name><surname>Reynolds</surname> <given-names>R</given-names></name><name><surname>McPeek</surname> <given-names>MS</given-names></name><name><surname>Cheng</surname> <given-names>S</given-names></name><name><surname>Ober</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Are common disease susceptibility alleles the same in outbred and founder populations?</article-title><source>European Journal of Human Genetics</source><volume>12</volume><fpage>584</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201191</pub-id><pub-id pub-id-type="pmid">15100713</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okita</surname> <given-names>K</given-names></name><name><surname>Matsumura</surname> <given-names>Y</given-names></name><name><surname>Sato</surname> <given-names>Y</given-names></name><name><surname>Okada</surname> <given-names>A</given-names></name><name><surname>Morizane</surname> <given-names>A</given-names></name><name><surname>Okamoto</surname> <given-names>S</given-names></name><name><surname>Hong</surname> <given-names>H</given-names></name><name><surname>Nakagawa</surname> <given-names>M</given-names></name><name><surname>Tanabe</surname> <given-names>K</given-names></name><name><surname>Tezuka</surname> <given-names>K</given-names></name><name><surname>Shibata</surname> <given-names>T</given-names></name><name><surname>Kunisada</surname> <given-names>T</given-names></name><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Takahashi</surname> <given-names>J</given-names></name><name><surname>Saji</surname> <given-names>H</given-names></name><name><surname>Yamanaka</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A more efficient method to generate integration-free human iPS cells</article-title><source>Nature Methods</source><volume>8</volume><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1591</pub-id><pub-id pub-id-type="pmid">21460823</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>JE</given-names></name><name><surname>Park</surname> <given-names>BC</given-names></name><name><surname>Kim</surname> <given-names>HA</given-names></name><name><surname>Song</surname> <given-names>M</given-names></name><name><surname>Park</surname> <given-names>SG</given-names></name><name><surname>Lee</surname> <given-names>DH</given-names></name><name><surname>Kim</surname> <given-names>HJ</given-names></name><name><surname>Choi</surname> <given-names>HK</given-names></name><name><surname>Kim</surname> <given-names>JT</given-names></name><name><surname>Cho</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Positive regulation of apoptosis signal-regulating kinase 1 by dual-specificity phosphatase 13A</article-title><source>Cellular and Molecular Life Sciences</source><volume>67</volume><fpage>2619</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1007/s00018-010-0353-3</pub-id><pub-id pub-id-type="pmid">20358250</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poché</surname> <given-names>RA</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Rueda</surname> <given-names>EM</given-names></name><name><surname>Tong</surname> <given-names>X</given-names></name><name><surname>McElwee</surname> <given-names>ML</given-names></name><name><surname>Wong</surname> <given-names>L</given-names></name><name><surname>Hsu</surname> <given-names>CW</given-names></name><name><surname>Dejosez</surname> <given-names>M</given-names></name><name><surname>Burns</surname> <given-names>AR</given-names></name><name><surname>Fox</surname> <given-names>DA</given-names></name><name><surname>Martin</surname> <given-names>JF</given-names></name><name><surname>Zwaka</surname> <given-names>TP</given-names></name><name><surname>Dickinson</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RONIN Is an Essential Transcriptional Regulator of Genes Required for Mitochondrial Function in the Developing Retina</article-title><source>Cell Reports</source><volume>14</volume><fpage>1684</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.01.039</pub-id><pub-id pub-id-type="pmid">26876175</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname> <given-names>MD</given-names></name><name><surname>McCarthy</surname> <given-names>DJ</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryazanov</surname> <given-names>AG</given-names></name><name><surname>Pavur</surname> <given-names>KS</given-names></name><name><surname>Dorovkov</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Alpha-kinases: a new class of protein kinases with a novel catalytic domain</article-title><source>Current Biology</source><volume>9</volume><fpage>R43</fpage><lpage>R45</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(99)80006-2</pub-id><pub-id pub-id-type="pmid">10021370</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname> <given-names>BP</given-names></name><name><surname>Shen</surname> <given-names>F</given-names></name><name><surname>Gardner</surname> <given-names>L</given-names></name><name><surname>Radovich</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Miller</surname> <given-names>KD</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Lai</surname> <given-names>D</given-names></name><name><surname>O'Neill</surname> <given-names>A</given-names></name><name><surname>Sparano</surname> <given-names>JA</given-names></name><name><surname>Davidson</surname> <given-names>NE</given-names></name><name><surname>Cameron</surname> <given-names>D</given-names></name><name><surname>Gradus-Pizlo</surname> <given-names>I</given-names></name><name><surname>Mastouri</surname> <given-names>RA</given-names></name><name><surname>Suter</surname> <given-names>TM</given-names></name><name><surname>Foroud</surname> <given-names>T</given-names></name><name><surname>Sledge</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-Wide association study for Anthracycline-Induced congestive heart failure</article-title><source>Clinical Cancer Research</source><volume>23</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0908</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname> <given-names>J</given-names></name><name><surname>Singh</surname> <given-names>NN</given-names></name><name><surname>Ottesen</surname> <given-names>EW</given-names></name><name><surname>Sivanesan</surname> <given-names>S</given-names></name><name><surname>Shishimorova</surname> <given-names>M</given-names></name><name><surname>Singh</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene</article-title><source>PLoS One</source><volume>11</volume><elocation-id>e0154390</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0154390</pub-id><pub-id pub-id-type="pmid">27111068</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serie</surname> <given-names>DJ</given-names></name><name><surname>Crook</surname> <given-names>JE</given-names></name><name><surname>Necela</surname> <given-names>BM</given-names></name><name><surname>Dockter</surname> <given-names>TJ</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Asmann</surname> <given-names>YW</given-names></name><name><surname>Fairweather</surname> <given-names>D</given-names></name><name><surname>Bruno</surname> <given-names>KA</given-names></name><name><surname>Colon-Otero</surname> <given-names>G</given-names></name><name><surname>Perez</surname> <given-names>EA</given-names></name><name><surname>Thompson</surname> <given-names>EA</given-names></name><name><surname>Norton</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial</article-title><source>Pharmacogenetics and Genomics</source><volume>27</volume><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1097/FPC.0000000000000302</pub-id><pub-id pub-id-type="pmid">28763429</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname> <given-names>JD</given-names></name><name><surname>Tibshirani</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Statistical significance for genomewide studies</article-title><source>PNAS</source><volume>100</volume><fpage>9440</fpage><lpage>9445</lpage><pub-id pub-id-type="doi">10.1073/pnas.1530509100</pub-id><pub-id pub-id-type="pmid">12883005</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname> <given-names>SM</given-names></name><name><surname>Whaley</surname> <given-names>FS</given-names></name><name><surname>Ewer</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Congestive heart failure in patients treated with doxorubicin</article-title><source>Cancer</source><volume>97</volume><fpage>2869</fpage><lpage>2879</lpage><pub-id pub-id-type="doi">10.1002/cncr.11407</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>SM</given-names></name><name><surname>Kagan</surname> <given-names>C</given-names></name><name><surname>Pavlovic</surname> <given-names>BJ</given-names></name><name><surname>Burnett</surname> <given-names>J</given-names></name><name><surname>Patterson</surname> <given-names>K</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reprogramming LCLs to iPSCs Results in Recovery of Donor-Specific Gene Expression Signature</article-title><source>PLOS Genetics</source><volume>11</volume><elocation-id>e1005216</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1005216</pub-id><pub-id pub-id-type="pmid">25950834</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibshirani</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Regression shrinkage and selection via the lasso</article-title><source>Journal of the Royal Statistical Society Series B (Methodological)</source><volume>58</volume><fpage>267</fpage><lpage>288</lpage></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohyama</surname> <given-names>S</given-names></name><name><surname>Hattori</surname> <given-names>F</given-names></name><name><surname>Sano</surname> <given-names>M</given-names></name><name><surname>Hishiki</surname> <given-names>T</given-names></name><name><surname>Nagahata</surname> <given-names>Y</given-names></name><name><surname>Matsuura</surname> <given-names>T</given-names></name><name><surname>Hashimoto</surname> <given-names>H</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name><name><surname>Yamashita</surname> <given-names>H</given-names></name><name><surname>Satoh</surname> <given-names>Y</given-names></name><name><surname>Egashira</surname> <given-names>T</given-names></name><name><surname>Seki</surname> <given-names>T</given-names></name><name><surname>Muraoka</surname> <given-names>N</given-names></name><name><surname>Yamakawa</surname> <given-names>H</given-names></name><name><surname>Ohgino</surname> <given-names>Y</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Yoichi</surname> <given-names>M</given-names></name><name><surname>Yuasa</surname> <given-names>S</given-names></name><name><surname>Murata</surname> <given-names>M</given-names></name><name><surname>Suematsu</surname> <given-names>M</given-names></name><name><surname>Fukuda</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes</article-title><source>Cell Stem Cell</source><volume>12</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.09.013</pub-id><pub-id pub-id-type="pmid">23168164</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tryka</surname> <given-names>KA</given-names></name><name><surname>Hao</surname> <given-names>L</given-names></name><name><surname>Sturcke</surname> <given-names>A</given-names></name><name><surname>Jin</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>ZY</given-names></name><name><surname>Ziyabari</surname> <given-names>L</given-names></name><name><surname>Lee</surname> <given-names>M</given-names></name><name><surname>Popova</surname> <given-names>N</given-names></name><name><surname>Sharopova</surname> <given-names>N</given-names></name><name><surname>Kimura</surname> <given-names>M</given-names></name><name><surname>Feolo</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>NCBI's Database of Genotypes and Phenotypes: dbGaP</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D975</fpage><lpage>D979</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1211</pub-id><pub-id pub-id-type="pmid">24297256</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Geijn</surname> <given-names>B</given-names></name><name><surname>McVicker</surname> <given-names>G</given-names></name><name><surname>Gilad</surname> <given-names>Y</given-names></name><name><surname>Pritchard</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>WASP: allele-specific software for robust molecular quantitative trait locus discovery</article-title><source>Nature methods</source><volume>12</volume><fpage>1061</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3582</pub-id><pub-id pub-id-type="pmid">26366987</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vejpongsa</surname> <given-names>P</given-names></name><name><surname>Yeh</surname> <given-names>ET</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities</article-title><source>Journal of the American College of Cardiology</source><volume>64</volume><fpage>938</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.06.1167</pub-id><pub-id pub-id-type="pmid">25169180</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visscher</surname> <given-names>H</given-names></name><name><surname>Ross</surname> <given-names>CJ</given-names></name><name><surname>Rassekh</surname> <given-names>SR</given-names></name><name><surname>Barhdadi</surname> <given-names>A</given-names></name><name><surname>Dubé</surname> <given-names>MP</given-names></name><name><surname>Al-Saloos</surname> <given-names>H</given-names></name><name><surname>Sandor</surname> <given-names>GS</given-names></name><name><surname>Caron</surname> <given-names>HN</given-names></name><name><surname>van Dalen</surname> <given-names>EC</given-names></name><name><surname>Kremer</surname> <given-names>LC</given-names></name><name><surname>van der Pal</surname> <given-names>HJ</given-names></name><name><surname>Brown</surname> <given-names>AM</given-names></name><name><surname>Rogers</surname> <given-names>PC</given-names></name><name><surname>Phillips</surname> <given-names>MS</given-names></name><name><surname>Rieder</surname> <given-names>MJ</given-names></name><name><surname>Carleton</surname> <given-names>BC</given-names></name><name><surname>Hayden</surname> <given-names>MR</given-names></name><collab>Canadian Pharmacogenomics Network for Drug Safety Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children</article-title><source>Journal of Clinical Oncology</source><volume>30</volume><fpage>1422</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.34.3467</pub-id><pub-id pub-id-type="pmid">21900104</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visscher</surname> <given-names>H</given-names></name><name><surname>Ross</surname> <given-names>CJ</given-names></name><name><surname>Rassekh</surname> <given-names>SR</given-names></name><name><surname>Sandor</surname> <given-names>GS</given-names></name><name><surname>Caron</surname> <given-names>HN</given-names></name><name><surname>van Dalen</surname> <given-names>EC</given-names></name><name><surname>Kremer</surname> <given-names>LC</given-names></name><name><surname>van der Pal</surname> <given-names>HJ</given-names></name><name><surname>Rogers</surname> <given-names>PC</given-names></name><name><surname>Rieder</surname> <given-names>MJ</given-names></name><name><surname>Carleton</surname> <given-names>BC</given-names></name><name><surname>Hayden</surname> <given-names>MR</given-names></name><collab>CPNDS Consortium</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children</article-title><source>Pediatric blood &amp; cancer</source><volume>60</volume><fpage>1375</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1002/pbc.24505</pub-id><pub-id pub-id-type="pmid">23441093</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Hoff</surname> <given-names>DD</given-names></name><name><surname>Layard</surname> <given-names>MW</given-names></name><name><surname>Basa</surname> <given-names>P</given-names></name><name><surname>Davis</surname> <given-names>HL</given-names></name><name><surname>Von Hoff</surname> <given-names>AL</given-names></name><name><surname>Rozencweig</surname> <given-names>M</given-names></name><name><surname>Muggia</surname> <given-names>FM</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Risk factors for doxorubicin-induced congestive heart failure</article-title><source>Annals of Internal Medicine</source><volume>91</volume><fpage>710</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-91-5-710</pub-id><pub-id pub-id-type="pmid">496103</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Benyamin</surname> <given-names>B</given-names></name><name><surname>McEvoy</surname> <given-names>BP</given-names></name><name><surname>Gordon</surname> <given-names>S</given-names></name><name><surname>Henders</surname> <given-names>AK</given-names></name><name><surname>Nyholt</surname> <given-names>DR</given-names></name><name><surname>Madden</surname> <given-names>PA</given-names></name><name><surname>Heath</surname> <given-names>AC</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Goddard</surname> <given-names>ME</given-names></name><name><surname>Visscher</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Common SNPs explain a large proportion of the heritability for human height</article-title><source>Nature Genetics</source><volume>42</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/ng.608</pub-id><pub-id pub-id-type="pmid">20562875</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>Y</given-names></name><name><surname>Tsunoda</surname> <given-names>T</given-names></name><name><surname>Doi</surname> <given-names>K</given-names></name><name><surname>Fujimoto</surname> <given-names>T</given-names></name><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Ota</surname> <given-names>T</given-names></name><name><surname>Ogawa</surname> <given-names>M</given-names></name><name><surname>Matsuzaki</surname> <given-names>H</given-names></name><name><surname>Kuroki</surname> <given-names>M</given-names></name><name><surname>Iwasaki</surname> <given-names>A</given-names></name><name><surname>Shirasawa</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Alpk2 is crucial for luminal apoptosis and dna repair-related gene expression in a three-dimensional colonic-crypt model</article-title><source>Anticancer Research</source><volume>32</volume><fpage>2301</fpage><lpage>2308</lpage><pub-id pub-id-type="pmid">22641666</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarubin</surname> <given-names>T</given-names></name><name><surname>Han</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Activation and signaling of the p38 MAP kinase pathway</article-title><source>Cell Research</source><volume>15</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/sj.cr.7290257</pub-id><pub-id pub-id-type="pmid">15686620</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname> <given-names>H</given-names></name><name><surname>Aizawa</surname> <given-names>K</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Tomida</surname> <given-names>S</given-names></name><name><surname>Otsu</surname> <given-names>K</given-names></name><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Mckinnon</surname> <given-names>PJ</given-names></name><name><surname>Manabe</surname> <given-names>I</given-names></name><name><surname>Komuro</surname> <given-names>I</given-names></name><name><surname>Miyagawa</surname> <given-names>K</given-names></name><name><surname>Nagai</surname> <given-names>R</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ataxia telangiectasia mutated in cardiac fibroblasts regulates doxorubicin-induced cardiotoxicity</article-title><source>Cardiovascular Research</source><volume>110</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw032</pub-id><pub-id pub-id-type="pmid">26862121</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Hou</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Wu</surname> <given-names>JL</given-names></name><name><surname>Xu</surname> <given-names>D</given-names></name><name><surname>You</surname> <given-names>X</given-names></name><name><surname>Pan</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of an adaptor protein that facilitates Nrf2-Keap1 complex formation and modulates antioxidant response</article-title><source>Free Radical Biology and Medicine</source><volume>97</volume><fpage>38</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.05.017</pub-id><pub-id pub-id-type="pmid">27212020</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.33480.049</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>McVean</surname><given-names>Gilean</given-names></name><role>Reviewing Editor</role><aff id="aff10"><institution>Oxford University</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Determining the genetic basis of anthracycline-cardiotoxicity by response QTL mapping in induced cardiomyocytes&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by Mark McCarthy (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal his identity: Douglas Sawyer (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This work presents a detailed analysis of how IPSCs from healthy volunteers can be used to investigate the molecular and cellular processes involved in differential response to a widely used chemotherapy, which has a high rate of adverse effects. The work provides new insights into the molecular functions, such as splicing, disrupted by doxorubicin, and some evidence that genetic factors that influence responses in gene expression correlate with risk for adverse events. Although previous work has established the value of IPSCs in this context, this paper presents several important advances.</p><p>Essential revisions:</p><p>I have chosen to include the individual reviews as each provides some useful insight. However, there are a few key features that should be addressed when revising the manuscript. I do not expect a full response to every comment raised by each reviewer – just the three highlighted here.</p><p>1) The reviewers noted that the evidence linking genetic risk for adverse responses to the genetics of gene expression regulation is rather weak. There are two suggestions for how to advance this. One is to use allele-specific expression to add power to the genetic response in expression analysis (reviewer 3).</p><p>2) A second suggestion is to provide a breakdown of the genetic enrichment in the GWAS data by QTL type – see reviewer 1. Also to revisit some of the genes discussed earlier in the paper in the light of the GWAS data.</p><p>3) The work should include a more detailed characterisation of the state of the IPSC lines – see reviewer 3 (point 3). This is part of the QC process and important to include.</p><p><italic>Reviewer #1:</italic> </p><p>This paper uses functional genomic and genetic analyses of iPSC cardiomyocytes to investigate the phenomenon of cardiomyocyte toxicity arising from anthracycline chemotherapy. Given the high frequency of this adverse effect and the widespread use of doxorubicin (and related compounds) this is an important problem, though as yet rather little understood. There has been quite a lot of previous and somewhat related work – notably Burridge et al., 2016. However, this paper goes beyond that by using iPSC from 45 healthy individuals (compared to the 3 with ACT and 3 without) and by integrating genetic data.</p><p>From my reading, I think the advances made by this paper are:</p><p>1) Replication of some of the Burridge et al. results about molecular functions and processes that are influenced by doxorubicin and their correlation with ACT response.</p><p>2) A much broader investigation of the dosage effects and variation among individuals. Ultimately, providing convincing evidence that the iPSC system provides a good model for ACT and that variation seen among iPSC lines correlates with ACT susceptibility in vivo.</p><p>3) Evidence to support the hypothesis that doxorubicin dysregulates gene splicing.</p><p>4) Evidence that there are a large number of genetic variants that affect expression responses to doxorubicin and that these show strong (but by no means complete) overlap with variants that affect gene expression in primary tissue.</p><p>5) Evidence that genetic variants that influence risk of ACT in patients are enriched for variants that also affect the expression of genes in response to doxorubicin.</p><p>Overall, there is a lot to admire in the paper. It is an extremely impressive and comprehensive use of functional genomics to probe the expression response to doxorubicin in cardiomyocytes. By focusing on variation among individuals, it provides compelling evidence that a strong stress response is a good biomarker for positive outcome. However, the primary focus of the paper concerns the genetic basis of this response – and the (strong and specific) claim being made is that understanding the genetic influences on doxorubicin response in iPSC cardiomyocytes provides biological insight into ACT susceptibility. Personally, I think this claim is rather weak for two reasons.</p><p>1) First, the Burridge et al. paper established the relevance of iPSC cardiomyocytes as a model for ACT, so the novelty of this paper rests on light being shed by the integration of genetic data on the iPSC lines. However, the majority of the genetic differences affecting doxorubicin response seem to be seen in GTEx tissues – with only a modest increase enrichment in heart compared to other tissues. The key question is whether reQTLs – i.e. those that are only visible through the doxorubicin treatment – are <italic>more</italic> relevant to ACT than general QTLs. Otherwise, to analyse the authors could have simply used the gene expression data from Burridge, the GWAS data and the GTEx data to arrive at similar conclusions. A concrete suggestion would be to stratify the enrichment in Figure 5B by general eQTL, cardiomyocyte (GTEx) eQTL and doxorubicin-specific reQTL.</p><p>2) Second, the enrichment reported in the GWAS data is really very weak – and certainly not strong enough to direct any future experiments. Put a different way – it doesn't appear to me that genes with strong doxorubicin reQTLs are particularly strong causal determinants of ACT risk. Conversely – I was surprised to find no further analysis of RARG – given that it is the only established GWS risk variant for ACT. While I am convinced that gene expression can be a useful biomarker for ACT, I don't think this paper establishes expression of any specific gene (or pathway) as causal for ACT susceptibility. I would like to see something like a Mendelian randomisation analysis of the response trait identified in Figure 4D to provide evidence to support a causal link.</p><p>In summary, this is a rather beautifully executed and analysed experiment, but the central claim – that genetic variation influencing gene responses to doxorubicin treatment in iPSC cardiomyocytes can be used to understand the biology of the phenomenon – is not convincing.</p><p><italic>Reviewer #2:</italic> </p><p>The Investigators took an interesting approach to understand the effects of anthracyclines on the heart, using iPSCs differentiated into cardiomyocytes from a series of subjects to test differential response to doxorubicin. They present an incredibly rich dataset showing the complexity of anthracycline-induced transcriptional changes that vary among individuals. They compare their findings to published GWAS studies exploring the same questions, and present their findings in a clear and thoughtful manuscript. The figures are clear and communicative. This noninvasive approach to utilizing human cells to study this clinically important problem is interesting and potentially very valuable. If applied to a group of samples from patients with and without anthracycline cardiotoxicity, it would be even more interesting as the findings would be more likely interpretable as related to the clinical risk of anthracycline induced cardiotoxicity.</p><p>The investigators chose to use samples from a Hutterite population, presumably based upon how the concept that this homogeneous population is good for identifying single gene Mendelian disorders. The genetic basis for cardiotoxicity of anthracyclines is likely more complicated. This limitation should be acknowledged by the authors.</p><p>Experimentally the investigators chose a range of doxorubicin concentrations that are high relative to what is likely the exposure of the heart in vivo in the context of clinical doxorubicin use. Extending the concentration range to 0.1 or even 0.05 μm would be worthwhile, as others have shown that cell toxicity can occur in this range in cells in vitro.</p><p>The investigators collected serum for cardiac Troponin T measurements, looking for in vitro signs of cytotoxicity. However there may be other forms of toxicity to the heart that occur without myocyte cytolysis, including the changes in transcription and splicing as presented here, as well as effects on endothelial and mesenchymal stem cells. Along these lines, is there any consideration for changes in other cell types, as iPSC cultures are heterogeneous. These issues should be acknowledged by the authors.</p><p>ACT can arise years after chemotherapy, it would be interesting to see if the cells were treated and then analzyed at a later timepoint than 24 hours to see if there are further differences than the acute changes after a 24 hour exposure.</p><p>In the Discussion the authors mention fibrosis playing a role in ACT. While this has been shown in human populations (e.g. PMID 29106497) using MRI, it is a relatively minor effect. The authors may want to update the references used to support the statement about fibrosis, as well as acknowledge it remains unclear how mechanistic this is in ACT.</p><p><italic>Reviewer #3:</italic> </p><p>This paper presents an analysis of interindividual variation in ips-derived cardiomyocyte gene expression following exposure to doxorubicin (dox).</p><p>The authors characterise differential expression and splicing patterns at different dox concentrations, and find good evidence that the in vitromodel they have developed represents a reasonably accurate simulation of ACT in vivo, with the activation of apoptosis and DNA damage repair pathways. They also map QTLs that modulate gene expression and splicing at different dox concentrations, and suggest that these are enriched for GWAS loci for ACT. The paper is well written, the figures are pretty clear and the analyses seem sound. The study is underpowered (n=45) and this places limitations on the conclusions that can be drawn, however, I don't find that they overstate their findings. I have the following major comments:</p><p>1) I was surprised that they didn't use allele-specific signals to boost power for association detection because the lead author has recently published a method for doing exactly this in the GxE setting (Knowles et al., 2017). I would like to see whether the GWAS / reQTL examples they highlight are supported by patterns of allele-specific expression, some discussion of why AS signals weren't used in the analysis and what impact this might have on their results.</p><p>2) They should try colocalisation of their eQTL (response and otherwise) with the ACT GWAS and report the appropriate summary stats (e.g. posterior probs of shared causality if using &quot;coloc&quot;), as this can be helpful for others who may want to follow up individual associations experimentally.</p><p>3) One issue with the use of IPSCs is that there can be substantial variation in the make-up of the cell populations created. I would like them to do a better job of characterising the composition and maturation status of the IPS CMs they have derived – there are existing markers that they can use to distinguishwhether they have made more atrial / ventricular-like CMs, and whether there is variation in CM maturity (for example in this review: http://www.sciencedirect.com/science/article/pii/S0167527317300517)</p><p>4) For comparison, they should compute the pi1 scores for their eQTLs across all GTEx tissues (not just heart, brain and LCLs).</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.33480.050</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>I have chosen to include the individual reviews as each provides some useful insight. However, there are a few key features that should be addressed when revising the manuscript. I do not expect a full response to every comment raised by each reviewer – just the three highlighted here.</p><p>1) The reviewers noted that the evidence linking genetic risk for adverse responses to the genetics of gene expression regulation is rather weak. There are two suggestions for how to advance this. One is to use allele-specific expression to add power to the genetic response in expression analysis (reviewer 3).</p></disp-quote><p>We have now incorporated an extension of EAGLE/WASP to the repeated measurements scenario and combined this signal with that from using suez on total expression. This increases the number of response eQTL (at 5% FDR) from 376 to 447 and improves the observed enrichment with the GWAS data. This improvement in power is somewhat modest which we hypothesize is due to a) suez already being reasonably well powered in this setting and b) the somewhat low sequencing depth of our samples.</p><disp-quote content-type="editor-comment"><p>2) A second suggestion is to provide a breakdown of the genetic enrichment in the GWAS data by QTL type – see reviewer 1. Also to revisit some of the genes discussed earlier in the paper in the light of the GWAS data.</p></disp-quote><p>We have added an extensive break-down of the enrichment in low GWAS p-values by expression and splicing QTL modality: steady-state in three different GTEx tissues, baseline (no doxorubicin) in our ICs, main effects only, main + response, and finally response eQTLs alone. We see substantial enrichment for our response QTLs, more moderate enrichment for the main effect IC eQTLs and no enrichment at all in the GTEx eQTLs, lending credence to the idea that response QTL mapping is valuable. Mapping response eQTLs using both total and allelic expression further improves the observed enrichment in the GWAS data.</p><p>In addition we have included an investigation of the role of the RARG variant in our data. Only two individuals in our panel are heterozygous the RARG variant (the rest are homozygous reference) but suez is able to detect 1 marginal effect and 5 response trans-eQTLs which represent candidate downstream mediators of the effect of RARG on ACT risk.</p><disp-quote content-type="editor-comment"><p>3) The work should include a more detailed characterisation of the state of the IPSC lines – see reviewer 3 (point 3). This is part of the QC process and important to include.</p></disp-quote><p>We have added extensive data supporting the validity of our iPSC panel (Figures 1—figure supplements 1-4). This includes qPCR for the major pluripotency genes, gene expression profiling analysis using PluriTest, embryoid body staining to confirm the ability of all our iPSC lines to differentiate into all three germ layers (images included in Supplementary Data) and assessment of EBV integration/expression.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…] Overall, there is a lot to admire in the paper. It is an extremely impressive and comprehensive use of functional genomics to probe the expression response to doxorubicin in cardiomyocytes. By focusing on variation among individuals, it provides compelling evidence that a strong stress response is a good biomarker for positive outcome. However, the primary focus of the paper concerns the genetic basis of this response – and the (strong and specific) claim being made is that understanding the genetic influences on doxorubicin response in iPSC cardiomyocytes provides biological insight into ACT susceptibility. Personally, I think this claim is rather weak for two reasons.</p><p>1) First, the Burridge et al. paper established the relevance of iPSC cardiomyocytes as a model for ACT, so the novelty of this paper rests on light being shed by the integration of genetic data on the iPSC lines. However, the majority of the genetic differences affecting doxorubicin response seem to be seen in GTEx tissues – with only a modest increase enrichment in heart compared to other tissues. The key question is whether reQTLs – i.e. those that are only visible through the doxorubicin treatment – are more relevant to ACT than general QTLs. Otherwise, to analyse the authors could have simply used the gene expression data from Burridge, the GWAS data and the GTEx data to arrive at similar conclusions. A concrete suggestion would be to stratify the enrichment in Figure 5B by general eQTL, cardiomyocyte (GTEx) eQTL and doxorubicin-specific reQTL.</p></disp-quote><p>We have added an extensive break-down of the enrichment in low GWAS p-values by expression and splicing QTL modality: please see response to editor above.</p><disp-quote content-type="editor-comment"><p>2) Second, the enrichment reported in the GWAS data is really very weak – and certainly not strong enough to direct any future experiments. Put a different way – it doesn't appear to me that genes with strong doxorubicin reQTLs are particularly strong causal determinants of ACT risk. Conversely – I was surprised to find no further analysis of RARG – given that it is the only established GWS risk variant for ACT. While I am convinced that gene expression can be a useful biomarker for ACT, I don't think this paper establishes expression of any specific gene (or pathway) as causal for ACT susceptibility. I would like to see something like a Mendelian randomisation analysis of the response trait identified in Figure 4D to provide evidence to support a causal link.</p></disp-quote><p>By using better powered meta-analyzed GWAS data, leveraging allelic-specific expression in the response eQTL mapping and breaking down the eQTLs into different classes we observe considerably stronger enrichment.</p><p>We have now added an investigation of the role of the RARG variant in our data – please see the response to the editor.</p><p>Unfortunately we don’t have sufficient sample size to perform a MR analysis for the transcriptomic response trait of Figure 4D directly. However, it is feasible to perform a Transcriptome-Wide Analysis Study (TWAS) for the effect of gene expression on troponin level. For each gene we built an elastic-net predictive model of expression at each doxorubicin concentration using SNPs within 100kb, with 10-fold cross- validation to choose the regularization parameters. The fitted predictions (known as the “pre-validation” values) then represent the genetically determined component of expression. We then used the 3840 genes with a statistically significant genetic component (at 1% FDR) to predict troponin level using leave-out-one-cross- validated (LOOCV) LASSO regression. 89% of the variance in troponin level can be explained by the genetic component of 102 genes. This analysis provides evidence for a causal link from genotype through gene expression to troponin level and highlights potential mediating genes. This TWAS approach here is analogous to two- stage least squares Mendelian Randomization.</p><disp-quote content-type="editor-comment"><p>In summary, this is a rather beautifully executed and analysed experiment, but the central claim – that genetic variation influencing gene responses to doxorubicin treatment in iPSC cardiomyocytes can be used to understand the biology of the phenomenon – is not convincing.</p><p>Reviewer #2:</p><p>The Investigators took an interesting approach to understand the effects of anthracyclines on the heart, using iPSCs differentiated into cardiomyocytes from a series of subjects to test differential response to doxorubicin. They present an incredibly rich dataset showing the complexity of anthracycline-induced transcriptional changes that vary among individuals. They compare their findings to published GWAS studies exploring the same questions, and present their findings in a clear and thoughtful manuscript. The figures are clear and communicative. This noninvasive approach to utilizing human cells to study this clinically important problem is interesting and potentially very valuable. If applied to a group of samples from patients with and without anthracycline cardiotoxicity, it would be even more interesting as the findings would be more likely interpretable as related to the clinical risk of anthracycline induced cardiotoxicity.</p><p>The investigators chose to use samples from a Hutterite population, presumably based upon how the concept that this homogeneous population is good for identifying single gene Mendelian disorders. The genetic basis for cardiotoxicity of anthracyclines is likely more complicated. This limitation should be acknowledged by the authors.</p></disp-quote><p>Previous work from the Ober and Gilad labs suggests that genetic mapping in the Hutterite population has value that extends beyond identifying Mendelian loci to complex traits, see e.g.</p><p>1) Yao, T.-C., Du, G., Han, L., Sun, Y., Hu, D., Yang, J.J., Mathias, R., Roth, L.A.,</p><p>Rafaels, N., Thompson, E.E., et al. (2014). Genome-wide association study of lung function phenotypes in a founder population. J Allergy Clin Immunol 133, 248-255.e241-210.</p><p>2) Cusanovich, D.A., Billstrand, C., Zhou, X., Chavarria, C., De Leon, S., Michelini, K., Pai, A.A., Ober, C., and Gilad, Y. (2012). The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes. Hum Mol Genet 21, 2111-2123.</p><p>3) Campbell, C.D., Mohajeri, K., Malig, M., Hormozdiari, F., Nelson, B., Du, G., Patterson, K.M., Eng, C., Torgerson, D.G., Hu, D., et al. (2014). Whole-genome sequencing of individuals from a founder population identifies candidate genes for asthma. PLoS ONE 9, e104396.</p><p>However, we agree that the Hutterites may not represent all genetic variation relevant to ACT, so we have included a new paragraph in the Discussion:</p><p>“We used a panel of Hutterites individual since this homogeneous population offers unique advantages for mapping genetic traits: exposure to a fairly uniform environment and less variable genetic background, despite still representing much of European diversity (Newman et al., 2004). We acknowledge however that the genetic basis of ACT susceptibility is clearly complex and some relevant genetic variation may not be well represented in this cohort.”</p><p><italic>Experimentally the investigators chose a range of doxorubicin concentrations that are high relative to what is likely the exposure of the heart</italic> in vivo <italic>in the context of clinical doxorubicin use. Extending the concentration range to 0.1 or even 0.05 μm would be worthwhile, as others have shown that cell toxicity can occur in this range in cells</italic> in vitro.</p><p>We agree it could be valuable to extend to lower concentrations. The concentrations we used are actually considerably lower than we used in a pilot study. Unfortunately performing these experiments across all cell lines would represent an experimental effort beyond the scope of the current work. We will consider this suggestion for future studies.</p><p><italic>The investigators collected serum for cardiac Troponin T measurements, looking for</italic> in vitro <italic>signs of cytotoxicity. However there may be other forms of toxicity to the heart that occur without myocyte cytolysis, including the changes in transcription and splicing as presented here, as well as effects on endothelial and mesenchymal stem cells. Along these lines, is there any consideration for changes in other cell types, as iPSC cultures are heterogeneous. These issues should be acknowledged by the authors.</italic> </p><p>We have added data showing that the average CM purity is 72% (minimum 41%). The fact that the most overlapping GTEx tissue with our eQTLs after the two heart tissues is fibroblasts suggests these may be represented. Unfortunately however it is challenging to tease apart potential cell-type specific effects with our bulk RNA-seq data. We have added a line to the Discussion to acknowledge this.</p><disp-quote content-type="editor-comment"><p>ACT can arise years after chemotherapy, it would be interesting to see if the cells were treated and then analzyed at a later timepoint than 24 hours to see if there are further differences than the acute changes after a 24 hour exposure.</p></disp-quote><p>As for the question of lower concentrations we agree this would be interesting but beyond our current scope.</p><disp-quote content-type="editor-comment"><p>In the Discussion the authors mention fibrosis playing a role in ACT. While this has been shown in human populations (e.g. PMID 29106497) using MRI, it is a relatively minor effect. The authors may want to update the references used to support the statement about fibrosis, as well as acknowledge it remains unclear how mechanistic this is in ACT.</p></disp-quote><p>Citation added and we have acknowledged the uncertainty in this finding.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…] I have the following major comments:</p><p>1) I was surprised that they didn't use allele-specific signals to boost power for association detection because the lead author has recently published a method for doing exactly this in the GxE setting (Knowles et al., 2017). I would like to see whether the GWAS / reQTL examples they highlight are supported by patterns of allele-specific expression, some discussion of why AS signals weren't used in the analysis and what impact this might have on their results.</p></disp-quote><p>We have now included an analysis jointly leveraging total and allele-specific expression, please see response to editor.</p><disp-quote content-type="editor-comment"><p>2) They should try colocalisation of their eQTL (response and otherwise) with the ACT GWAS and report the appropriate summary stats (e.g. posterior probs of shared causality if using &quot;coloc&quot;), as this can be helpful for others who may want to follow up individual associations experimentally.</p></disp-quote><p>We have now performed this analysis. While for 40/43 tested genes (with reQTL p&lt;1e-5 and GWAS p&lt;0.05) the posterior probability of colocalization is higher than for independent signals, both the GWAS and eQTL data are underpowered for this type of analysis and <italic>coloc</italic> estimates the highest posterior probability for no association for 32/43 genes.</p><disp-quote content-type="editor-comment"><p>3) One issue with the use of IPSCs is that there can be substantial variation in the make-up of the cell populations created. I would like them to do a better job of characterising the composition and maturation status of the IPS CMs they have derived – there are existing markers that they can use to distinguishwhether they have made more atrial / ventricular-like CMs, and whether there is variation in CM maturity (for example in this review: http://www.sciencedirect.com/science/article/pii/S0167527317300517)</p></disp-quote><p>We have added extensive characterization of the iPSCs and estimates of cardiomyocyte purity (see response to editor above).</p><disp-quote content-type="editor-comment"><p>4) For comparison, they should compute the pi1 scores for their eQTLs across all GTEx tissues (not just heart, brain and LCLs).</p></disp-quote><p>We’ve now done this across 48 tissues, please see Figure 2A and Figure 2—figure supplement 2 and Figure 5—figure supplement 5. We found that while there are a small number of tissues that have higher pi1 scores than the heart tissues (Figure 5—figure supplement 5) this is likely due to confounding with differential power across the GTEx tissues: an analysis designed to account for the differential power clearly shows the heart tissues having the strongest overlap (Figure 2—figure supplement 2) out of all the GTEx tissues.</p></body></sub-article></article>